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The development of the postnatal mammary gland is tightly controlled by peptide
hormones and cytokines. The signaling of these extracellular ligands through their
corresponding receptors rely on Janus Kinases (JAKs) that activate downstream Signal
Transducers and Activators of Transcription (STATs). The JAK/STAT signaling pathway
is crucial for processes such as growth, proliferation, and cell survival of the epithelial
tissue, but also for the breakdown and remodeling of the mammary gland via IL-6 class
inflammatory cytokines (e.g. LIF and OSM). JAK1 and JAK2, which are expressed in the
mammary gland, are thought to have redundant functions. However, our previous
studies demonstrated that JAK2 is exclusively required for the activation of STAT5 as
well as the growth and functional differentiation of the gland. In contrast to the general
paradigm, JAK2 might be dispensable for the activation of STAT3 in response to IL-6
class inflammatory cytokines. Utilizing the recently generated JAK1 conditional knockout
mouse model, we demonstrate that Janus kinase 1 is the essential kinase responsible
for mediating inflammatory cytokine signaling in the mammary gland, specifically during
postlactational remodeling events where the absence of JAK1 delayed involution.

Ablation of JAK1 in the mammary epithelium of mice dramatically prevented the
activation of STAT3 and uncoupled signaling of IL-6 class ligands such as OSM and LIF
from their downstream effectors. Completing the profile of STATs, JAK1 was also found
to play a non-redundant role in the activation of STAT1 and STAT6 but not STAT5.
Building on the evidence that JAK1 contributes to the activation of STAT3 in nontransformed mammary epithelial cells, we next tested if JAK1 maintained discretion in
the activation of STAT3 in neoplastic tissue. A notorious transcription factor, active
STAT3 has been tightly linked to aggressive disease, promoting a metastatic phenotype
in breast cancers, notably, a subset of which that overexpress the human epidermal
growth factor ErbB2/Her2. Using the mammary-specific deletion of JAK1 in the context
of ErbB2 oncogenesis, we found that while JAK1 does not affect the tumor onset, it
dramatically decreases STAT3 activity and occurrence of metastasis. Interestingly, we
found that JAK1 is also required for the tumor-initiating cell population of established
disease.
Collectively, the results of these studies describe the novel role of Janus kinase 1
specifically in mammary gland development and the contribution of JAK1 to disease
progression.
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Chapter 1
Introduction

1

1.1.

Structure and Function of Janus Kinases and STATs

1.1.1.

Activation of JAKs and STATs
Mammalian systems have an abundance of growth factors, peptide hormones,

and cytokines, and rely on these ligands to initiate and promote physiological changes
such as growth, proliferation, or conversely, apoptosis. Signaling of these extracellular
ligands through their corresponding receptors rely on Janus Kinases (JAKs) to activate
downstream Signal Transducers and Activators of Transcription (STATs). Upon ligand
binding, the corresponding receptor will recruit membrane receptor-associated Janus
kinases which then autophosphorylate at tyrosine residues and become activated.
Activated JAKs will provide phosphorylation on tyrosine sites of their associated
receptor. These activated tyrosine sites provide a docking site for intracellular signal
transducers and activators of transcription (STATs). Following recruitment to the
receptor, STATs will be activated by JAKs through phosphorylation at tyrosine residues.
On the STAT protein, the modification promotes binding sites of Src Homology 2
domains of subsequent STAT proteins. Binding produces a stable homo- or
heterodimerization of the STATs, allowing the transcription factors to undergo
translocation to the nucleus, where they bind DNA and affect transcription activity.
While there are four members of the JAK family are JAK1, JAK2, JAK3, and TYK2,
each are able to phosphorylate select STATs of the seven-member family (STAT1,
STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6). The crucial determinate to
exploring which JAK that will activate a STAT protein is likely context-dependent, first
taking into consideration the tissue and initiating ligand.

2

Fig. 1.1.

3

Figure 1.1. The JAK/STAT signaling pathway. The activation of the JAK/STAT signal
transduction pathway begins with 1) the unbound receptor that binds with its
corresponding ligand. 2) The binding induces a conformation change, recruits a Janus
kinase that will auto-phosphorylate and create docking sites for the unbound STAT
proteins. 3) The phosphorylated, and now active STATs dimerize and translocate to the
nucleus where they recognize and bind GAS consensus sequences, initiating
transcription of target genes. Among the regulators within the pathway are suppressors
of cytokine signaling (SOCS) which inhibit active JAKs, protein tyrosine phosphatases
(PTPs) that function to dephosphorylate JAKs as well as STATs, and protein inhibitors of
activated STATs (PIAS), which can inhibit the translocation of STATs to the nucleus.

4

1.1.2 Structure and function of Janus kinases
Janus kinases are comprised of seven domains and are described by homology
between the Janus kinases, referred to as Jak homology (JH) domains. Their hallmark
characteristics are the tandem kinase domains, discovered in 1989 by Wilks et al.,
during the initial cloning [1, 2]. When it was first discovered, the kinase was named JAK,
for ‘Just Another Kinase’, until it was found to have the two kinase domains, with one
lacking enzymatic activity. It was aptly renamed ‘Janus kinase’, modeling the Roman
two-faced god of the gates and doorways [3-6]. The first domain at the C-terminus is
JH1 and is the catalytically active site. The second domain, JH2 is the catalytically
inactive, pseudokinase domain, which could serve as a negative regulator for the
catalytic domain, substrate localization, or supply a structural role in supporting the
catalytic JH1 domain [7, 8]. The family also shares five other homology domains,
directed from C to N-terminus. JH3 holds the src-homolgy 2 (SH2) domain, and little is
known about its function. The remaining region, JH4-7, contains the four-point-one,
ezrin, radixin, moesin (FERM) domain. The FERM domain is thought to coordinate with
the cytoplasmic portion of the cell receptor, as a study explored the truncated aminoterminus of JAK2 and observed the kinase lost its ability to associate with the growth
hormone receptor [9] (Fig. 1.2. Top). The resulting protein ranges from 120-140 kDa in
size.

1.1.3 Developmental Analysis: Knockout models of the Janus kinases
To understand the biological implications in development of the Janus kinase
family, knockout models have been generated. Conventional deletion refers to the target
gene being inactivated in all cells of the organism. Conditional models are an elegant
tool used to not only bypass embryonic lethality that is commonly seen in conventional
models, but also an effective way to excise genes in a temporal and spatial manner.

5

Knockout models have been generated to address the role of several Janus
kinases in development. Janus kinase 2 was found to have the most severe phenotype,
embryos died in utero near embryonic day 12.5, due to inadequate erythropoiesis [10,
11]. To circumvent the lethality during gestation, a conditional Jak2 mouse model was
generated, and in concordance with observations made from the germ line knockout,
JAK2 has been shown to mediate the signaling of growth hormone (GH), erythropoietin,
as well as prolactin [12-15]. Additionally, conditional knockout models describe integral
function of JAK2 in mediating signaling in gonadotropin-releasing neurons [16]. The
commonality of the ligands is that they are associated with single-chain receptors.
Janus kinase 3 is mainly restricted to the hematopoietic compartment,
associating with the common gamma chain of interleukin (IL) receptor-2, IL-4, IL-7, IL-9,
and IL-15 [17, 18]. Deletion of Jak3 was not lethal, and mice were viable and fertile,
although when Jak3-deficeint mice were analyzed, the role of JAK3 and gamma chain
receptors was confirmed, as mutant mice were found to have a thymocyte phenotype as
ablation of Jak3 resulted in severe lymphopenia, a decrease of the B and T cells [19].
Janus kinase 1 knockout mice have been generated, and mutant mice lacking
the tyrosine kinase die shortly after birth due to neurologic defects and its effects had not
been addressed in adult tissue. In the 1998 study, analysis of collected cardiomyocytes,
macrophages, and embryonic fibroblasts demonstrate that Jak1 may be responsible for
cytokines such as IL-2, IL-6, LIF, and IFN [20]. In order to address the response of cells
from these ligands in postnatal development, a conditional knockout would need to be
generated.
The fourth member of the JAK family, and first to be identified during a search
for tyrosine kinases, is Tyrosine kinase 2 (TYK2) [21, 22]. The knockout revealed a
partial dependency of this JAK family member for the response of IFN α/β and gamma,
as well as IL-12. The phenotypic role was described by Karaghiosoff et al. to have a
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predominate effect in the immune response, specifically in select antiviral mechanisms
[23]. In contrast to the other JAK family members, TYK2 had redundant role in mediating
receptor complex activation, although it had a crucial role in innate and adaptive immune
responses.

1.1.4 Structure of STATs
The STAT proteins carry two roles in the cascade of signaling events, the first
being signal transduction, carrying the signal after becoming activated by a Janus kinase
and the second is activating transcription. STATs perform the later by translocating to
the nucleus as a dimer and bind to recognition sequences on the DNA, the gamma
interferon activation sites (GAS), recognizing consensus sequences, TTCNNNNGAA.
STATs are composed of five domains: the amino-terminus, DNA-binding, SH3-like, SH2, and the carboxy-terminus transactivating domain (Fig. 1.2. Lower). Both the aminoterminus and the DNA-binding domains are highly conserved between the STAT
members. The DNA-binding domain will interact with the DNA. The C-terminal activating
domain is also conserved among the STAT proteins. The tyrosine in this domain, once
phosphorylated allows for the subsequent dimerization at the SH2 domain, mediating the
binding partners (other STAT proteins). Dimerization occurs as homo dimers between
STATs or as heterodimers. Whether a one dimerization occurs over another is context
and STAT-dependent, as some STATs are exclusive for only forming one or the other
and with specific STATs. Such as, STAT1 and STAT3 can heterodimerize with one
another, and STAT2 will only form a heterodimer with STAT1, and but will not form a
homodimer [24].
Serine phosphorylation has been reported in the case of STAT1 and STAT3, at S727 at
the

C-terminus

(Wen 1995)

Zhang

1995),

and may enhance the tyrosine

phosphorylation, although the two activation events may be independent of each other.
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Fig. 1.2.

9

Figure 1.2. Structure of the Janus kinase and STAT protein. The Janus kinase (top)
is comprised of seven JAK homology domains (JH), regions that share similarity
between the four family members. JH1 serves as the catalytically active kinase domain,
followed by the JH2, psuedokinase domain. The amino-terminal FERM domain interacts
with the cytoplasmic portion of the receptor. The STAT protein (lower) contains the
domains necessary for protein-protein interaction, the amino-terminus domain and the
coiled-coil domain. The DNA-binding domain recognizes consensus sequences in the
DNA. The SH2 domain is responsible for the tyrosine phosphorylation at the receptor
and recruitment with other STAT proteins.
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1.1.5 Developmental Analysis: Knockout models of the STAT proteins
STAT1 deficiency is most apparent in IFN signaling, where STAT1 null mutants
have decreased signaling efficiency in response to type1 and II IFNs [25, 26]. These
knockout models produced a truncated protein with no activity (Mera, et al.) or an
elimination of STAT1 protein (Durbin et al.). STAT1 knockout mice were viable, although
extremely susceptible to viral infections. Conditional knockout models were later
developed in 2010 [27], and later in 2011, which targeted exons 6-10, the DNA-binding
domain, for deletion [28]. Using the myloid-specific promoter driving Cre recombinase,
LysM-Cre,

macrophages

and

neutrophils

were

analyzed

and

confirmed

the

unresponsiveness of cells to IFN signaling.
Park et al, generated the STAT2-deficient mouse and while they were viable,
they were found to be deficient in IFN signaling and like the STAT1 knockout mice, also
susceptible to viral infections [29].
A whole-body knockout of STAT3, generated by deletion of the SH2 domain and
tyrosine residue, was reported to be embryonic lethal [30]. The 1997 by Takeda et al.,
saw degeneration of embryos as gestation day 6. Since then, tissue-specific STAT3
knockouts in T-cell, macrophages and neutrophils, keratinocytes, and the mammary
gland have been analyzed [31]. STAT3-deficient T cells displayed impaired proliferation
due to an impaired response to IL-6 signaling [32]. Macrophages and neutrophils lacking
STAT3 had decreased IL-10 production, and experienced inflammatory response
mediated by high levels of TNF-alpha, IFN-gamma, and IL-1 [33, 34]. Skin tissue was
analyzed for the deletion of STAT3 [35], using the Keratin5-Cre promoter and was found
to have decrease wound healing thought to be from the deceased motility of cells during
epidermal regeneration, such as neovascularization and response to inflammation. On a
closer look, the in vitro studies demonstrated that while proliferation of STAT3-deficient
epidermal cells was unaffected, a migration assay of cells compared to wild type, a
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knockout of STAT3 severely impaired the motility of cells. The function of STAT3 was
addressed in the mammary gland by specifically deleting the transcription factor using
the beta-lactoglobulin (BLG) promoter driving Cre recombinase expression [36]. The
study was the first to describe that STAT3 played a prominent role in the remodeling of
the gland after offspring weaning, by suppressing apoptosis.
STAT4 knockout mice had no observable phenotype and were viable, although
studies have shown STAT4 to be highest in the spleen and testes [37]. STAT4 was
demonstrated to mediate IL-12 signaling in both organs, specifically in the spleen STAT4
decreased the cytolytic activity of cytotoxic T cells, and a STAT4 deficiency phenocopied
an IL-12 knockout [38, 39].
STAT5 has two isoforms, STAT5a and STATb and conventional models
generated are viable [40, 41]. STAT5a knockout mice display a phenotype during
pregnancy, where mammary gland development is impaired. STAT5b mice experienced
growth-retardation caused by a decreased response to growth hormone (GH) [40].
Conditional models have addressed the role of STAT5 in the hematopoietic system and
mammary gland development. The role of STAT5 in the context of stem cell transplants
provided evidence that total STAT5 inhibition could promote tissue engraftment [42].
Similar to the STAT4 model, mice deficient in STAT6 did not display a noticeable
phenotype, but were responsible for the select ligand signaling of IL-4 [4, 43]. Mice
lacking STAT6 lacked efficient class switching and full upregulation of B cells.
The use of in vivo models opens the possibility to depict the full biological
process and roles of select genes and their proteins. Genetically engineered mouse
models allow for describing the role of the gene in development using conventional
whole-body knockouts as well as its function in select tissue using tissue-specific gene
deletions.
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Table 1.1. Phenotypes: Murine models of Jak knockouts
Gene

Knockout:
Conventional/Conditional

Tyk2

Conventional

Jak1

Conventional

Conventional
Conditional, mammary
gland

Jak2

Jak3

Phenotype
Viable, impaired
antiviral immune
response.
Embryonic lethal,
pups died shortly
after birth, neurologic
defects.
Embryonic lethal,
inadequate
erythropoiesis

Reference
Karaghiosoff et al

Rodig, et al. 1998.
Neubauer, et al. 1998
Parganas, et al. 1998
Krempler, et al. 2004

Impaired
alveologenesis

Wagner, et al. 2004

Conditional,
neuroendocrine

Reduced fertility,
impaired signaling
involving
gonadotropin
releasing hormone

Wu, et al. 2012

Conditional, hepatocytes

Decreased oxidative
stress, fatty liver

Conditional, adipocytes

Reduced lipolysis

Themanns, et al. 2016
Sos, et al. 2011
Shi, et al. 2012
Nordstrom, et al. 2013

Conditional, hematopoietic

Anemia, lethal

Grisouard, et al. 2014

Conventional

Viable, severe
lymphopenia

Nosaka, et al. 1995

Table 1.1. Knockout murine models for Janus kinase family members. Knockout
models have been generated and phenotypes observed in whole body knockouts
(conventional) or in a tissue specific manner (conditional).
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Table 1.2. Phenotypes: Murine models of Stat knockouts
Gene

Stat1

Stat2

Knockout:
Condtional/Conventional
Conventional
Conditional,
macrophages,monocytes,
neutrophils
Condtional,
Mammary gland
Conventional
Conventional
Conditional, T-cells

Stat3

Conditional, macrophages,
neutrophils
Conditional, keratinocytes
Conditional, mammary
gland

Stat4

Conventional

Conventional, STAT5a

Stat5

Conditional, mammary
gland
Conventional, STAT5b
Conditional, hematopoietic

Stat6

Conventional

Phenotype

Reference

Viable, impaired IFN
response
Viable, impaired IFN
response

Meraz, et al. 1996

Viable, increased
tumor burden
Viable, impaired IFN
signaling
Embryonic lethal
Viable, impaired IL-6
signaling
Increased Th1
response
Viable, impaired
wound healing
Viable, delayed
mammary gland
remodeling
Viable, fertile,
impaired IL-12
signaling
Viable, impaired
alveologenesis and
failure to lactate in
female mice
Impaired
development. Loss of
differentiated
alveolar cells
Dwarfism,
deregulated liver
dimorphism
Limited
hematopoietic stem
cell population
Viable, deregulated
IL-4 response

Klover, et al. 2010

Wallner, et al. 2012
Durbin, et al. 2012

Park, et al.
Takeda, et al. 1997
Takeda, et al. 1998
Takeda, et al. 1999
Sano, et al. 1999
Chapman, et al. 1999
Thierfelder, et al.
1996
Liu, et al. 1997

Cui, et al. 2004

Udy, et al. 1997
Wang, et al. 2009
Takeda, et al. 1996
Shimoda, et al. 1996
Kaplan, et al. 1996

Table 1.2. Knockout murine models for STAT family members. Deletion of individual
STATs during development as a whole-body knockout (conventional) or targeted to specific
tissues (conditional) demonstrate the critical function the proteins have in signal
transduction.
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1.2.

JAKs and STATs in Mammary Gland Biology

1.2.1 Overview of Mammary Gland Development
The postnatal mammary gland undergoes dramatic structural changes
throughout its development cycle. The majority of growth is seen in the nascent gland at
the time of birth. The most prolific growth occurs throughout puberty followed by
changes associated with pregnancy, and also addresses the remodeling of the gland
following offspring weaning. Throughout development, the organ experiences robust
controlled growth, cellular proliferation, as well as massive orchestrated cell death.
This development cycle is tightly regulated by peptide hormones and cytokines,
which elicit specific responses in the cells of the gland. Signaling of these extracellular
ligands through their corresponding receptors rely on Janus Kinases (JAKs) to activate
downstream Signal Transducers and Activators of Transcription (STATs). The
JAK/STAT signaling pathway is crucial for processes such as growth, proliferation, and
cell survival, but also for the breakdown and remodeling of the mammary gland after the
cessation of lactation. Of the four JAK family members, (JAK1, JAK2, JAK3, and Tyk2)
the predominately expressed Janus kinases in the mammary gland are JAK1 and JAK2.
Currently, both kinases are thought to have redundant functions in the activation of
selected STAT proteins. However, studies have shown that JAK2 is exclusively required
for the activation of STAT5. JAK2/STAT5 then drives growth and functional
differentiation of the gland in response to growth hormone and prolactin. In contrast to
the general paradigm of redundancy between the two kinases, JAK2 may be
dispensable during the remodeling process. The mammary gland experiences rapid
decrease in circulating growth hormones and a rise in IL-6 class inflammatory cytokines
(e.g. LIF and OSM) in the transition from lactation to involution. These inflammatory
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cytokines are mediated by a Janus kinase to activate STAT3, which promotes genes
involved in matrix remodeling and apoptosis.

1.2.2 Postnatal Mammary Gland Development
Development of the murine mammary gland begins as early as embryonic day
10.5, when two milk lines begin to appear. Derived from the ectoderm, five symmetrical
placodes form along each milk line at embryonic day 11.5 [44]. These placodes grow
into the epidermis near day 14 of development to initiate the characteristic epithelial
buds. This establishes the epithelial mesenchyme and elongation of the bud protrudes
into the underlying fat pad, producing a small ductal tree[45]. The continued
development occurs after birth.
In females, the architecture of the ductal tree remains constant until
approximately 4 weeks of age, estrogen rises during puberty and growth in the
mammary gland is again stimulated. Proliferation occurs by ductal branching from the
terminal end buds. The repeated estrous cycles promote branched network of ducts and
will continue growth to fill the mammary fat pad until 10 weeks of age. At this stage the
mature virgin mammary gland will stop growing, until prompted by a surge of growth
hormones induced by pregnancy.
The mammary gland is composed of many cell types. Adipose, immune cells,
and fibroblasts are found in the stroma, while a bilayer of cells composes the alveolar
and ductal epithelium. The bilayer consists of myoepithelial and luminal cells.
Connecting to the basement membrane, myoepithelial cells are basally located while
luminal cells are oriented apically. The luminal cells will function to secrete milk during
pregnancy.
Pregnancy induces a large, regulated proliferation in the ductal network, this time
as tertiary structures that terminate in alveolar buds. The alveolar buds give rise to the
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robust growth of the differentiated luminal epithelial cells to form alveoli. These cells will
secrete milk during lactation, which will empty into the ducts to feed offspring. The
alveolar cells are maintained throughout lactation, but when offspring are weaned the
terminally differentiated luminal cells are no longer needed. The differentiated alveolar
cells undergo cell death as the entire gland shifts into the next phase of development,
known as postlactational remodeling.
The remodeling event, also termed involution, is a dramatic example of
orchestrated cell death. The apoptosis is necessary for the clearance of differentiated
alveolar cells. The process of involution proceeds in two steps. The first reversible stage
being massive programmed cell death of the differentiated alveolar cells. The second is
irreversible, as organ undergoes architectural restructuring as the gland returns to its
pre-pregnancy state. This stage involves breakdown of the basement membrane and
clearance of the apoptotic cells. The once-maintained epithelium regresses and is
replaced by adipose tissue. This reset prepares the gland for subsequent pregnancies.

1.2.3 Mammary Gland Development is Orchestrated by Hormones and Locally
Produced Cytokines
The postnatal development of the mammary gland is regulated by growth factors,
hormones, and locally derived cytokines. Initially, the gland responds to long-range
endocrine hormones produced by the ovaries for the formation and elongation of ducts.
Estrogen and progesterone mediate the ductal branching at the onset of puberty and
during estrous cycles for the development into mature virgin glands. Peptide factors
such as FGF and IGF have also been shown to promote ductal outgrowth and
lobuloaveolar development[46, 47]. The growth factor amphiregulin, transcriptionally
regulated by ERα acts through EGF receptors to also promote ductal growth [48]. The
known pregnancy hormone, prolactin, is the prominent driver for cell proliferation and
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survival of the secretory alveolar cells during pregnancy and the maintenance of the
epithelium during lactation.
When offspring are weaned, the secretory alveolar cells need to be removed,
shifting survival signals to apoptosis. Locally derived growth factors facilitate the
involution process. As circulating levels of prolactin decline, IL-6 class inflammatory
cytokines rise. These inflammatory cytokines include, Oncostatin M (OSM) and leukemia
inhibitory factor (LIF), although, IL-6 itself does not play a role in signaling during
involution [49]. In addition, soluble factors and members of the interleukin family (IL-1α,
IL-1β, and IL-13) [50, 51], and TGF-β3 are present [52]. The secretion of TNFα also
signals for the recruitment of macrophages, aiding in the clearance of cell debris.
Although they are contrasting molecular events, the signals of lactation and
involution, together with development of the organ as a whole, share the general signal
transduction pathway.

1.2.4 Peptide hormones and locally synthesized cytokines that are essential for
MG development utilize particular JAK/STAT pathways for intracellular signaling
Circulating hormones and growth factors initiate their effects in the mammary
gland by binding to their corresponding receptors, and as most cytokine receptors lack
intrinsic kinase activity, they recruit a Janus kinase to become active. The active JAK will
autophosphorylate and create binding site for Signal Transducers and Activators of
Transcription (STATs). The STAT proteins will become activated by phosphorylation,
dimerize, and translocate to the nucleus to bind to the DNA, promoting gene
transcription. STATs may promote cell survival or cell death signals, depending on the
upstream hormone or cytokine signal and activating Janus kinase.
The JAK family is comprised of four members: JAK1, JAK2, JAK3, and tyrosine
kinase 2 (TYK2). Primarily restricted to the hematopoietic system, JAK3 and TYK2 are
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necessary for immune function, while JAK1 and 2 are more ubiquitously expressed[53].
In the mammary gland, JAK1 and JAK2 are recognized as being the prominent Janus
kinases, mediating signaling of cytokines to activate downstream STATs by tyrosine
phosphorylation. There are seven members in the STAT family: STAT1, STAT2, STAT3,
STAT4, STAT5a, STAT5b, and STAT6. In the mammary gland, all are expressed with
the exception of STAT2, which is found in the immune system. The activation of the
STAT proteins varies according to the stage of mammary gland development. Prompted
by growth and proliferation signals during pregnancy and subsequent lactation, STAT5 is
the main driver for genes associated with cellular differentiation and survival. STAT1 has
been demonstrated to be active in the stroma to promote ductal branching [54]. IL-4
initiates activation of STAT6 and phenotypically, the early pregnant mammary glands of
STAT6-deficient mice are shown to have impaired alveolar growth, although this was
less apparent during late pregnancy [55]. The non-deleterious effects of STAT1 or
STAT6 in the mammary gland suggest these transcription factors play subordinate roles
in development. In contrast to cell-sustaining events, following lactation and the
induction of mammary gland remodeling, STAT3 becomes the prominent transcription
factor, inducing transcription of genes necessary to breakdown epithelial cells. The
activity of the appropriate STAT protein in stages of mammary gland development is
determined by specific growth hormones, cytokines, and a distinct Janus kinase.
In the case of prolactin (PRL), the pregnancy-associated hormone binds to the
prolactin receptor (PRLR). The dependence of alveolar cell growth on this pathway is
defined by PRLR-null mice, upon pregnancy, alveolar buds failed to proliferate in
response to PRL [56, 57]. The receptor recruits Jak2 then activating STAT5 to promote
the AKT/PI3K pathway, upregulating genes associated with proliferation, differentiation,
and cell survival [58]. The association of JAK2/STAT5 and mammary epithelial cell
differentiation is well documented by in vitro and animal studies. Mice deficient in STAT5
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specifically in the mammary epithelium failed to produce alveolar buds and undergo
proliferation in response to prolactin stimulation[59]. A conditional deletion of Jak2 [60] in
the mammary gland parallels the STAT5 phenotype, as ligand binding fails to activate
the receptor and subsequent lack of STAT5 activation. Both studies phenocopy a
prolactin receptor-deficient model, such as the mammary glands that lack any of the
previous demonstrate loss of alveolar bud formation[56].

1.2.5 Postlactational Remodeling and Inflammation
The remodeling event is a necessary phase of mammary gland development and
is the most dramatic series of organized cell death in the organism. The purpose is to
terminate the functionally differentiated cells utilized during pregnancy and lactation,
allowing the gland to reorganize into a virgin-like state before another pregnancy takes
place. Beginning shortly after the offspring are weaned, the remodeling proceeds in two
phases. The first phase is characterized by the apoptosis of epithelial cells no longer
needed for milk secretion. The second phase includes cell death and also the
breakdown and remodeling of the gland, replacing alveolar cells with adipocytes[61].
Inflammatory cytokines are necessary to initiate each phase. As prolactin levels
decrease, inflammatory cytokines, leukemia inhibitory factor (LIF) and oncostatin M
(OSM) are locally produced. Common to the family members of IL-6 class inflammatory
cytokines, OSM receptor (OSMR) and LIF receptor (LIFR) require a GP130 subunit to be
activated by a Janus kinase[62]. The phosphorylation by the Janus kinase allows the
signal to be relayed from the plasma membrane to the nucleus via activated STAT
proteins. These transcription factors will to bind to or complex with other transcription
factors to drive transcription of genes necessary for cell death machinery and matrix
remodeling. Given the commonality in the IL-6 signal transduction, the key convergence
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at which a specific Janus kinase activates the receptor may represent a mechanism to
specifically target the inflammatory pathway.
The prominent signal transducer and activator of transcription necessary for
mammary gland remodeling is STAT3. Conventional knockout mice identified that a
STAT3 deficiency proved embryonic lethal [30]. Bypassing embryonic lethality,
conditional deletion of STAT3 within the mammary gland verified STAT3 activity in
remodeling [36]. Proceeding studies identified that loss of STAT3 and its tyrosine
phosphorylation domain inhibited remodeling [63]. In fact, a loss of STAT3 is two-fold, as
it extends the functionality of the gland and delays involution [64]. Previous work has
described the integral function of LIF for the initial activation of STAT3, in the first stage
of remodeling, as LIF-deficient mice have an absence of phosphorylated STAT3 and
delayed mammary gland remodeling [65, 66]. Delayed remodeling is also seen in gp130deficeint mice [67]. This initial activation of STAT3 transcriptionally upregulates LIF
receptor (LIFR), along with STAT3, and oncostatin m receptor (OSMR) creating a feedforward loop, perpetuating the activation of STAT3 by OSM, as LIF levels diminish
leading into the second phase of remodeling[36]. Extensive tissue remodeling coupled
with removal of the apoptotic cells in the second, irreversible phase concludes involution
and the gland is prepared for a subsequent pregnancy.
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1.3.

JAKs and STATs in Disease

1.3.1 Roles of Inflammatory Cytokine Signaling in Cancer
As one of the hallmarks of cancer, inflammation has long been associated with
cancer progression and aggressive disease [68, 69]. Categorically separated into acute
and chronic, inflammation attributing to disease is typically the later, as perpetual
exposure of the inflammatory milieu may induce plasticity in epithelial cells. At the site of
chronic inflammation, increases in immune cells, primarily macrophages, and cytokines
are common. As chemical messengers, cytokines associated with inflammation can
induce tissue repair and remodeling. Prevalent cytokines include tumor necrosis factor
(TNF) and interleukin family members such as IL-6, IL-10, and IL-21. Cytokine signals
from the environment as well as from cancer cells themselves illicit the activation primary
cytokines and transcription factors such as nuclear factor kappaB and STAT3. Important
for cell growth- STAT3 has been implicated in mediating the transformation of both
human and murine cells, contributing to cancer, particularly when constitutively active
[70]. Whereas normal cells have tight regulation on STAT3 activation, cancer cells have
unrestricted STAT3 activity, fueling cell growth and metastatic potential. In a model of
human prostate cells expressing a constitutively active STAT3, it was shown that STAT3
had the capability to transform cells and modify the actin cytoskeleton thereby promoting
migration [71]. Epithelial-Mesenchymal Transition STAT3 has also found a role in stem
cells, as studies have linked its activity in regulating tumor-initiating cells [72-74].
The cytokine interleukin 6 (IL-6) has been described to have many functions
throughout the body. Functioning from hematopoiesis to the endocrine system the cell
types that respond to IL-6 range from macrophages to cells of the heart, liver, and ovary
[75]. In inflammatory hepatocellular adenoma, it was demonstrated that Representative
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of the many roles for IL-6 within the body, it’s apparent in a disease setting that the
presence of IL-6 is not the issue but rather the persistent production of the cytokine.
Likewise, the increased or sustained inflammatory signaling perpetuates STAT3 activity,
such as the case in inflammatory hepatocellular adenoma and hepatocellular carcinoma
[76, 77]. Cheng et al., demonstrated IL-6 promoted tumor growth and metastasis in a
STAT3-dependant manner in a murine model of breast cancer [78].
The importance of knowing the biological function of Janus kinases is crucial
when targeting these kinases in disease. Mouse models of breast cancer clearly
demonstrate that inhibiting JAK2 prior to disease onset results in substantial decrease of
tumor formation[79]. This implies that JAK2 is a rational preventive therapy in human
malignancy. However, JAK2 is dispensable not only for tumor growth in established
disease but also for STAT3 tyrosine phosphorylation, clearly indicating that inhibiting
STAT3 requires an alternative target [80]. Persistent activation of STAT3 downstream of
IL-6 signaling is well documented in disease progression. While there are attempts at
inhibiting STAT3, by targeting the SH2 domain or DNA-binding domain, directly inhibiting
STAT3 remains difficult, as it is a latent transcription factor until activated [81]. Perhaps
an efficient strategy to limit the DNA-binding activity of the transcription factor is
distinguishing its activator in specific tissues and malignancies.

1.4.

Generation of a Jak-1 Conditional knockout Model

1.4.1. Rationale for Pursuing the Generation of a Conditional Knockout
Since 1998, no published attempts have been made to analyze Janus kinase 1 in
postnatal development via knockout. In the seminal study by Schreiber, the first two
coding exons of Jak1 were replaced by a neomycin cassette, rendering a disrupted
allele [20]. This disruption produced a null protein in both a heterozygous cross as well
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as a homozygous breeding. This conventional, whole-body knockout resulted in
offspring that experienced perinatal lethality. Thus, the functional role of Janus kinase in
adult tissue was unable to be performed. What was observed was momentous, in a way,
as the study pointed to a non-redundant biological role for Janus kinase 1, in mediating
the signaling of several subfamilies of cytokine receptors (class II cytokine receptors:
IFNα/β, IFNy, and IL-10, the yc receptor: IL-2, IL4, IL-9, and the gp130 receptor subunit
class: IL-6, OSM, LIF). The observations and conclusions were made from assessing
Jak1

wild

type

and

Jak1-deficient

macrophages,

embryonic

fibroblasts,

and

cardiomyocytes.
As JAK1 had been implicated to be central in the signaling node for several
cytokine receptors, it was left to question whether the same signaling cascades would be
mediated in a similar way in vivo in postnatal development. To address the biological
function of JAK1 in postnatal development, a spatial and temporal model to delete Jak1
would need to be designed.

1.4.2. Construct Design
Detailed accounts of generating the conditional knockout mouse model can be
found in the 2016 publication by Sakamoto, et al [82]. The targeting vector was
generated using bacterial artificial chromosome (BAC) recombineering as described
previously by Sakamoto, et al, 2014 [83]. Director of the UNMC Mouse Genome
Engineering Core Facility, Dr. Channabasavaiah Gurumurthy

provided valuable

assistance to Dr. Sakamoto in the generation of the targeting vector. To construct a
conditional knockout allele of Jak1 gene, homologous recombination was used to insert
loxP sites around exon 2 (floxed allele), and was generated in mouse embryonic stem
(ES) cells at the UNMC Mouse Genome Engineering Core Facility. Thirteen correctly
targeted ES cell clones were identified and two were injected into C57Bl/6 blastocysts.
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Chimeric animals were produced and germ line transmission of the Jak1fl/fl allele was
achieved. Further breeding of heterozygous mice identified offspring with both Jak1
floxed alleles (homozygous Jak1fl/fl mice). Mice carrying both mutant alleles developed
normally, regardless of gender and were fertile.

1.4.3. Breeding Scheme and Phenotypic Characteristics
Recombination occurs when Cre recombinase is present. The recombinase will
specifically recognize the loxP sites and will excise the DNA fragment between two
directly oriented loxP sites. From the Jak1

fl/fl

construct design, recombination would

delete exon 2, causing a frameshift of the coding sequence, resulting in an absence of
protein. To analyze whether our recently generated Jak1 conditional knockout mouse
would phenocopy that of the previously published conventional knockout , the floxed
allele of Jak1 was transmitted in the germline of MMTV-Cre mice (line A) [84], as the
developing oocytes express active Cre recombinase [85]. Transgenic female mice
carrying the MMTV-Cre and Jak1fl/wt genes were bred, activating the Cre recomibinase in
the oocyte and thereby deleting one allele of Jak1. The progeny were screened by PCR
and observed that Jak1wt/- mice developed normally and were fertile. These observations
support the 1998 study of the conventional Jak1 knockout, where one allele deficiency
did not promote a dominant-negative phenotype. To generate Jak1-null offspring, Jak1
heterozygous mice (Jak1-/+) were crossed. To rule out early embryonic lethality, fetuses
at embryonic day 12.5 through 18.5 were collected. In total, 43 embryos were collected
and were near an expected Mendelian ratio, as 9 (21%) of the embryos were Jak1deficient, 22 (51%) were heterozygous, and 12 (28%) were wild type. In our observation
of the embryos at day 12.5, homozygous null, heterozygous, and wild type were
indistinguishable from one another. Although, at embryonic day 15.5, 17.5, and 18.5, the
Jak1-deficient fetuses were noticeably smaller in size compared to wild type embryos.
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While observing Jak1 knockout offspring, pups survived birth and were able to move
similar to wild type pups, but had noticeably more difficult time breathing, with longer
pauses or gasps similar to apnea. Knockout mice perished 30 minutes to 2 hours after
birth. Similar to Rodig et al., the newly generated Jak1 knockout phenotypically mimics
the reported conventional deletion.

1.4.4. Molecular Characteristics of a Jak1-deficiency
To confirm the deletion of Jak1 on the molecular level, PCR was used to identify
wild-type or null alleles in developing embryos, and murine embryonic fibroblasts were
derived from embryonic day 12.5 for primary and immortalized cell cultures. Cells were
derived from Jak1 wild-type, heterozygous and knockout embryos for biochemical
analysis (see Materials and Methods: Generation of Murine Embryonic Fibroblasts). The
MEFs deficient in Jak1 were not exclusively dependent on the kinase for survival in 2D
culture, as they grew and proliferated at the same rate as the wild type. Immunoblotting
was performed on the MEF cells, and the Jak1 deletion was confirmed in the
homozygous null fibroblasts, confirming that the deletion of exon 2 resulted in the
absence of protein [86]. As well, a minor reduction in protein was seen in the
heterozygous cells. The total levels of JAK2 remained constant, although interestingly, at
the steady-state level, the cells exhibited a loss of activated STAT3, as detected by
Western blot. The loss of tyrosine (T705) phosphorylation was evident, although serine
phosphorylation (S737) was unchanged, suggesting that a JAK1-independent
mechanism is needed for serine activation. The predominant modification is tyrosine
phosphorylation for STATs to localize to the nucleus, and it has been proposed that
serine and tyrosine activation are not interdependent. In analyzing other members of the
STAT family, the activation of STAT1 and STAT6 were also ablated in the absence of
Jak1.
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1.4.5 Conclusions from Generation of the Janus kinase Knockout model
In conclusion, the generation of the conditional deletion of Jak1 mirrors that of
the previously reported conventional, whole body knockout of Jak1 [20]. The recently
generated data from Sakamoto et al., 2016, suggests that this kinase is necessary for
the tyrosine activation of three members of the STAT family, as analyzed by in vitro data.
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1.5.

Conclusion and Dissertation Hypothesis
The JAK/STAT pathway has many functions in development and tissue

homeostasis, yet also contributes to disease progression and maintenance, and thus
has been a target in cancer. Specifically in breast cancer, the premise that STATs can
contribute to cancer initiation and survival is well-studied, but the concise identification
and the biological function of their upstream activators has been less explored.
Through prior exploration of JAK/STAT signaling in the mammary gland, it is
evident that the pathway is crucial not only for processes such as growth, proliferation,
and cell survival, but also for the breakdown and remodeling of the gland via IL-6 class
inflammatory cytokines (e.g. LIF and OSM). The two members of the Janus kinase
family that are expressed within the mammary epithelium, JAK1 and JAK2, have
generally been thought to have redundant functions in STAT activation. This is due, in
part, to the emphasis on JAK2 in mammary studies and also the lack of data and
appropriate genetic tool to investigate the postnatal role of JAK1 in development. We
have demonstrated that JAK2 is exclusively required for the activation of STAT5,
promoting growth of the gland and also contributing to alveolar proliferation [60]. The
involution events have characterized STAT3 as the prominent STAT protein driving
expression of genes necessary for remodeling the gland [36]. Still, the upstream kinase
responsible for STAT3 activation is unclear, as both JAK1 and JAK2 are thought to
mediate the inflammatory cytokines. In contrast to the general paradigm, JAK2 may be
dispensable for involution events and mediating IL-6 class inflammatory cytokines, and
resulting activation of STAT3. Supporting this premise, we have observed a persistent
activation of STAT3 in mammary tumor cell lines that are genetically deficient in Jak2
[80], indicating that another Janus kinase may be responsible for STAT3 signaling.
Therefore, we hypothesize that the Jak1 signaling cascade is an important factor in
inflammatory cytokine signaling and has a role in postlactational remodeling of the
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normal mammary gland and as inflammatory cytokines play a significant role in cancer
development, Jak1 may contribute to neoplastic transformation and malignant
progression. To approach these questions, we will first determine whether ablation of
Jak1 affects normal mammary gland remodeling. Second, we will analyze the
importance of Jak1 signaling in mammary carcinogenesis.
The purpose of this work is to identify the molecular contribution of JAK1 to STAT
activation, characterize the function and biological relevance of JAK1 in adult mammary
tissue, and identify its implications in breast cancer.
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Chapter 2: Materials & Methods
Materials & Methods
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Mouse Colonies and Strains Used
The use of rodents for studies in this body of work is approved by the Institute for
Animal Care and Use Committee (IACUC). Mouse colonies were maintained according
to IACUC protocol and standards, and monitored by UNMC Comparative Medicine.
Animals were treated fairly and humanely. Premature euthanasia was employed when
any signs of distress appeared in mice during the course of the studies such as impaired
movement, pain, and lack or eating or drinking. Mice were first euthanized by applying
anesthesia by CO2 followed by cervical dislocation, as recommended by American
Veterinary Medical Association.
The MMTV-Cre strain was used to target recombination events specifically to the
mammary gland. The Jak1fl/fl strain was recently generated and used as a littlemate
control to double transgenic experimental mice MMTV-Cre Jak1fl/fl.
Tumor studies utilized the MMTV-neu strain, amplifying the neu oncogene in a
mammary-specific manner. The CAG-lox-CAT-lox-GFP model was utilized as a visual
aid for recombination events. Athymic nude, FoxN1nu/nu, from National Cancer Institute
were used for orthotopic transplant studies.

Table 2.1. Mouse Models Utilized
Mouse Model
MMTV-Cre (A line)
MMTV-neu
Jak1fl/fl
CAG-lox-CAT-lox-GFP
NCr-Foxn1nu

Background
FVB
FVB
FVB
FVB
NCr

Reference
Wagner et al., 1997
Muller et al., 1988
Sakamoto et al., 2016
Kawamoto et al., 2000
National Cancer Institute

Whole mount analysis
The thoracic (referred to as number three mammary glands) or the abdominal
mammary (referred to a number four mammary glands) glands were dissected out and
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spread onto a glass microscope slide (3” x 1” x 1mm, Fisher Scientific) and placed in
Carnoy’s fixative solution for at least 1 hour or up to three days. Carnoy’s fixative: 6 parts
100% EtOH, 3 parts CHCL3, and 1 part glacial acetic acid. Fixative was kept in 50mL
Falcon tubes, where the tissue on glass slide was placed. Fixative reused. The
mammary gland on glass slide was then washed in 70% EtOH for 15 minutes and
gradually changed to distilled water. Gland was rinsed in distilled water for 5 minutes.
The gland was then placed in Carmine Alum Stain in 4’C overnight or for up to one week
(depending on stain penetration). Carmine Alum Stain: 1 g Carmine (Sigma C1022) and
2.5 g aluminum potassium sulfate (Sigma A7167) in 500 mL distilled water and boiled for
20 minutes. Final volume was adjusted to 500 mL with distilled water. Carmine was
filtered and a crystal of thymol was added as a preservative. Completed stain was stored
at 4’C and used for several months. After Carmine Alum stain, gland was washed in
gradients of EtOH for 15 minutes each (70%, 95%, and 100%). Glands were transferred
to xylene for 6 hours or up to three days and then mounted with Permount mounting
medium (Fischer Scientific, SP15-100). Whole mounts were visualized using the Zeiss
Stereo microscope (Carl Zeiss).

Extracting DNA
Tissue was gathered for genotyping by snipping 0.5cm from end of mouse tail
(typically 4 weeks of age) and digested overnight at 56’C in a Digestion Buffer solution.
Digestion buffer was comprised of Tail Buffer: (for 500mL buffer) 1% SDS (50mL of 10%
solution), 50nM TrisHCl pH8 (25mL of 1M solution), 100nM NaCl (10mL of 5M solution),
and 50 mM EdTA (50mL of 0.5M solution) and Proteinase K (PK), 10mg/ml. For each
sample, 500 uL of Tail buffer and 20 uL of PK were used. DNA was extracted by
mechanical means, using the AutoGenprep2000 (all reagents used proprietary to
AutoGen and contain phenol, ethanol, I-Butanol 9%, Iso Amyl Alcohol 0.01%, and
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isopropanol 40%) and maintained high levels of DNA yield and quality. In the event that
the mechanical extraction was used, DNA was extracted by hand using the following
protocol: Each sample (in 1.5mL tube) was suspended in Digestion Buffer (700 uL of Tail
Buffer and 30 uL of PK) and digested overnight at 56’C. The samples were then briefly
vortexed and spun down at 13,000 RPM for 20 minutes at room temperature. The
supernatant was then poured off into new 1.5 mL tube and 600 uL Phenol added
(Invitrogen, 15513-047). The tube was gently inverted 7 times to mix and centrifuged at
13,000 RPM for 20 minutes. The top layer (containing water and DNA) was pipetted off
and placed into new 1.5 mL tube and 600 uL chloroform (Fisher BP1145-1) added,
inverted 7 times to mix and centrifuged at 13,000 RPM for 20 minutes. The top layer was
carefully pipetted off and placed into a new 1,5 mL tube and 1 mL of 100% EtOH and
was added and the tube gently inverted 7 times to precipitate the DNA, and spun at
13,000 RPM for 20 minutes, The supernatant was poured off and the DNA pellet was
dried by laying the tube on its side for 15 minutes. 100 uL TE (Fischer Scientific,
BP2473-1) was added to resuspend the DNA.

Genotyping
Extracted genomic DNA was then analyzed by polymerase chain reaction (PCR)
to verify the presence or absence of specific genetic modifications. A single PCR
reaction was comprised as follows: A final reaction volume of 50uL was made of 32.5uL
of ddH2O, 10uL of 5x PCR reaction buffer (Promega, M890A), 3uL MgCl2 (25mM,
Promega, A351H), 1uL of dNTPs (10mM, Invitrogen), 0,5uL each of forward and reverse
primer (made through IDT, 100pM), 0.5uL of 5U/uL Taq DNA polymerase (Promega,
M829B), and 1uL of genomic DNA template. Primer sets utilized and PCR conditions in
Table 2.2. PCR programs were run on a T3 Thermocycler (Biometra). PCR product run
on a 0.8% agarose gel (BioExpress, E-3119-500), dissolved in 1xTAE buffer (Tris-
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Acetate-EDTA) (Fisher Scientific, BP1332-20) containing ethidium bromide (Ameresco,
X328-10ML). Gel was visualized using BioDoc-It Imaging System (UVP).

Preparation of murine tissue for analysis
Histology
Tissue was removed, cut several times to allow increased buffer penetration, and
placed in 10% buffered formalin (Fisher Healthcare, 245-684) in a 20 mL scintillation vial
for 24 hours. After 24 hours, the formalin was poured off and discarded in appropriate
waste container and the tissue was resuspended in 70% EtOH for long-term storage.
Tissue was prepared for paraffin embedding by placing tissue in tissue cassette and
processing and embedding according to manufacturers directions using the Thermo
Scientific Excelsior AS (an automated system that processes tissue starting from 70%
EtOH, water, and progressing to dehydrant solution, Clearant solution, and wax). Tissue
was embedded with the Thermo Scientific Histostar. The embedded tissue was
sectioned using a microtome, cutting tissue 4 uM thick onto microscope slides (Fisher
Scientific, 12-550-15). The slides were baked at 56’C overnight and stored in slide
boxes.

Hematoxylin & Eosin
The staining protocol has been optimized to produce strong nuclear stain by
hematoxylin and resilient cytoplasmic stain by eosin. Beginning with paraffin embedded
tissue sections, deparaffinize in three changes of 100% Xylene (Histo-Clear II, National
Diagnostics, HS- 202) for 5 minutes each, followed by two 5 minute changes in 100%
EtOH , and two changes each in 95% EtOH, 3 minutes each. Rinse briefly in distilled
H2) and incubate slides in Hematoxylin (Fisher HealthCare, 220-100) for 20 minutes.
Rinse slides in glass slide box briefly in running tap water, avoiding direct running water
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contact with the slides, until water is clear. Also be sure to use cold water, as warm
water will fade staining. Dip slides into acid alcohol solution (1%HCl in 70& EtOH)
followed by a brief rinse in tap water. Next, slowly dip slides into ammonia water solution
(1 mL NH4OH in 1L H2O), here the sections should darken slightly. Rinse again in tap
water, briefly, and then incubate in Eosin Y (Statlab, SL98-32) for 1-2 minutes
dependent on desired intensity. Rinse briefly under tap water. Place slides into 95%
EtOH for several seconds, here esosin will come off slightly. Move slides to 100% EtOH
and incubate in two changes for 5 minutes each, to fully dehydrate slides before placing
in 100% Xylene. Incubate in Xylene for 10 minutes to 1 hour and mount using Permount
and coverslip. Slides were viewed and using a Zeiss Axio Imager microscope (Carl
Zeiss) and images captured using SPOT Flex camera and SPOT 5.1 software
(Diagnostic Instruments).

Immunofluorescence and Immunohistochemisty
Immunostaining on fixed-formalin paraffin embedded tissue
The protocol is designed for formalin-fixed paraffin embedded tissue, addressing
immunofluorescence (IF). Tissues were deparaffinized in 100% Xylene (3 incubations for
10 minutes each) and rehydrated in decreasing concentration of EtOH (2 incubations in
100% for 3 minutes each, and one incubation of 3 minutes each of 95%, 90%, 70%,
50%, and 30%) finishing with a final 5 minute wash in 1xPBS (Fisher Scientific BP399-1,
diluted 1:10 in ddH2O) for 3 minutes. Slides went through antigen retrieval, using 938 uL
of Antigen Unmasking Solution (Vectastain, H-3300) into 100 uL ddH2O. Solution was
pre-warmed first before adding to slides. 45mL of prepared Antigen Unmasking Solution
were added to slides in 50 mL conical tubes, and heated (avoiding boil) for 20 minutes at
a power level of 1. Slides were left to cool to room temperature in solution before rinsing
in 1xPBS for 5 minutes. Slides were marked with hydrophobic pen, and tissue area
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blocked with 3%BSA (1.5% BSA, Sigma, A9418-100G, powder, dissolved in 50mL of 1x
PBS) for 1 hour. Slides were rinsed for five minutes in 1xPBS. Primary antibody added,
diluted to desired concentration in blocking buffer. Only one section of the two on the
slide received primary antibody, the other received only blocking buffer for background
staining control. Primary incubation carried out overnight in a moist chamber at 4°C. The
following day slides were rinsed three times in 1xPBS for 5 minutes each. Secondary
antibody was applied to all tissue, diluted in blocking buffer, appropriate to primary
antibody host and reporter fluorophore. Care was taken to perform tasks in low light to
avoid diminishing secondary antibody fluorescence. Secondary antibody incubated in
moist chamber for 1 hour, away from light, at room temperature. Slides washed twice in
1xPBS for 5 minutes each followed by one wash in ddH2O for 5 minutes to remove salts
that may increase background staining. One drop of Vectasheild DAPI mounting media
(Vector, H-1200) was added per tissue and coverslipped. Sealed with clear nail polish,
and stored away from light at 4°C. Primary and secondary antibodies used for both
immunofluorescence and IHC listed in Table 2.3 . Slides were then visualized using
Zeiss Axio Imager A1 (Carl Zeiss) and images taken using SPOT Imaging Software 5.1
2014.
To perform immunohistochemistry (IHC), all steps are similar to the IF protocol,
from deparaffinization and through rehydration.

After rehydration, background

peroxidase was treated with a 30 minute incubation in a 3% H2O2 (Fisher, H325-500)
solution in methanol. (EMD Millipore, MX0475-1). Sildes were rinsed and then treated by
antigen retrieval and blocked as in the IF protocol. Primary antibodies for IHC are listed
in Table 2.3 and diluted in blocking buffer. Slides were incubated overnight in moist
chamber in 4°C. The next day, biotinylated secondary antibody was prepared using the
Vector ABC staining kit (Vector PK-6101, PK-6102), diluted 1:200 in blocking buffer.
ABC reagent was prepared by adding 1 drop of each reagent A and B into 5 mL of
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1xPBS, vortexed, and incubated at room temperature for 30 minutes. Slides were rinsed
of secondary antibody in 1xPBS for 5 minutes and ABC reagent added and incubated for
30 minutes in a damp chamber at room temperature. Slides were rinsed in 1xPBS for 5
minutes while DAB reagent (3,3-diaminobenzadine, a peroxidase substrate) was
prepared (Vector labs, SK-4100). Slides were dried slightly and DAB was added to
slides and watched as staining intensity developed under light microscope. Reaction
was terminated by placing slides in tap water. Slides were counterstained in hematoxylin
for 10 seconds and rinsed with cold tab water. Slides were dehydrated in reverse
process as the rehydration steps and mounted.

IHC for pSTAT1
The following protocol was used for the identification of pSTAT1 (Origene pYSTAT1, TA309955) in mouse tissue. Used IDetect™ Universal Mouse Kit-HRP
(IDSTM003). IHC protocol was followed through from deparaffinization to rehydration.
Next, slides were treated with detergent permeabilization, 0.02% Tween 20 in 1xPBS for
20 minutes, then washed in 1xPBS. Antigen retrieval is same as previously described
IHC then cooled to room temperature for 1 hour. Slides were then treated for
endogenous peroxidase with 3% H2O2 in methanol for 20 minutes, then washed 3 times
in 1xPBS for 3 minutes each. Super Block (part of kit) added for 7 minutes, incubated
room temperature after circling tissue with hydrophobic pen. Slides washed 3 times in
1xPBS 3 minutes each. Universal Mouse Block (part of kit) added to tissue, incubated
for 1 hour, then washed 3 times in 1xPBS. Primary antibody was diluted 1:100 in 1%
BSA in 1xPBS and incubated overnight at 4°C in moist chamber. Next day slides
washed 3 times in 1xPBS and biotinylated secondary antibody, Anti-Polyvalent, added
for 20 minutes (part of kit), incubated at room temperature. Washed 3 times in 1x PBS,
then HRP (part of kit) added, incubated 20 minutes at room temperature. Washed 3
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times in 1xPBS, then stained with DAB reagent (prepared as described previously) until
reaction developed. Counterstain, dehydration, and mounted as described previously.

Immunoblotting Protocol
Tissue and cells were prepared for Western blot (WB) by resuspending in
prepared complete lysis buffer. Complete lysis buffer, a mixture of RIPA buffer and
proteinase inhibitors, is prepared as follows: RIPA buffer: (radioimmunoprecipitation lysis
buffer, which will lyse cells and solubilize proteins, used for whole cell extracts and
membrane bound proteins) contains: 0.1% SDS, a denaturing detergent, 0.5% sodium
deoxycholate for protein/protein disruption, 1% Nonidet P-40, in 1xPBS, stored at 4°C.
Proteinase inhibitors are as follows: Sodium orthovanadate (Sigma, S6508), PMSF
(Stock solution of 10mg/mL in isopropanol): Leupetin (Midwest Scientific, J580-2, stock
at 10mg/mL in ddH2O), Aprotinin (Sigma #A6279), and Sodium fluoride (Fisher
Scientific, S299-100, stock solution 1M in ddH2O). Quantities of reagents to add for
complete lysis buffer are as follows: For final volume of 500 uL, 471 uL of RIPA buffer, 9
uL of PMSF, and 5 uL each of aprotinin, leupeptin, sodium orthovanadate, and sodium
fluoride were combined and vortexed.
Cell pellets were prepared for immunoblot by resuspending in 50-150 uL of
complete lysis buffer in 1.5 mL tubes, on ice, and lysed using the Fisher Scientific Model
500 Sonic Dismembrator, amplitude set to 13 and pulsed for 3 seconds, twice, with
resting 30 seconds on ice in between. Cells were placed on ice for 20 minutes followed
by centrifugation at 13,000 RPM for 30 minutes at 4°C. The resulting supernatant was
moved to a new 1.5 mL tube and quantified by Bradford reaction using BSA protein
standard in Coomassie Plus Protein Assay Reagent (Thermo Scientific, 1856210) for
standard curve. 25-75 ug of protein was prepared for analysis by adding 25 uL of TrisGlycine SDS sample buffer (Novex, LC2676) and 1 uL of beta-mercaptoethanol (Fisher
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Scientific, BP176-100) to each sample and boiled for 10 minutes at 100’C. Samples
were placed immediately on ice before loaded onto 4-20% SDS-PAGE gel (Invitrogen,
XP04200BOX). Gels were run for 1 hour at 80 volts followed by120 volts for 1.5 hours.
Gel was transferred onto solid support PVDF membrane filter paper, 0.2um pore size
(Novex, LC2002). Transfer was run at 17mAMPs for 1 hour followed by 30mAMPs for 1
hour. Membrane blocking was in 5% dry milk in 1xTBST (Tris-buffered saline with 0.05%
Tween-20) buffer or 3% BSA in 1xTBST for phosphorylation-detecting antibodies, for 1
hour at room temperature, rocking. Membranes were washed in 1xTBST and primary
antibody applied in appropriate concentration for overnight incubation, rocking, at 4°C.
Next day membranes washed 3 times 5 minutes each before HRP-conjugated
secondary antibody added in appropriate concentration in blocking buffer for 1 hour,
room temperature. Protein was detected using the ECL chemiluminescence kit (GE,
Amersham, RPN2106). For further probing on same membrane, membranes stripped
using 0.2M sodium hydroxide solution for 15 minutes. Film used for exposure
(BioExpress, F-9029-8X10) List of antibodies used, Table 2.3. The Janus kinase 1
antibody was generated in the lab of Dr. Hallgeir Rui and kindly shared. Sodium azide
(Sigma, S8032) was used to extend primary antibody use in buffer (several crystals
added per 10mL antibody cocktail prepared), this aided in reusing antibody several times
before discarding.
Tissue was prepared for WB by suspending in complete lysis buffer, 200- 500uL,
dependent on tissue size and homogenized twice, 5 seconds each, to dissociate cells,
samples incubated on ice for 20 minutes. The remaining steps follow protocol written
above.

Generating Expression Vectors
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To facilitate expression of selection markers or target genes, the following vector
constructs were used: pHIV-dTomato (Gift of Bryan Welm, Addgene plasmid #21374),
pHIV-ZsGreen (Gift of Bryan Welm and Zena Werb, Addgne plasmid #1812) [87]. The
pHIV-Luciferase-ZsGreen was generated using the pHIV-ZsGreen construct was
digested with BamHI and Not1 overnight, the next day calf intestinal phosphatase (CIP)
was added for one hour to limit self-ligation. The T7-IRES-Luciferase (cloned by KayUwe Wagner, PhD) luciferase insert was PCR amplified and digested with BamHI and
Not1. The backbone and insert were ligated overnight and transformed in Top10 cells.
Clone “g” was used for virus production.
The

shJAK1

TRCN0000003105)

was
and

generated

cloning

into

using
the

shJAK1

(TRCN0000003102

Tet-pLKO-puro

(Gift

from

and

Dmitri

Wiederschain, Addgene #21915) [88], with AgeI and EcoRI.
The pHIV-FOS-dTomato was generated using the pHIV dTomato construct,
digested with HbaI and XbaI overnight. The pcDNA3-FLAG-Fos WT was a gift from John
Blenis (Addgene #8966) [89], and was digested with Asp718, then subsequently
digested with Xba1. The backbone and insert were ligated overnight and transformed in
DH5α cells. Virus was made from DNA isolated from clone “A”. The pHIV-caSTAT3dTomato was generated using the pHIV dTomato backbone and STAT3-C (pMXs-Stat3C was a gift from Shinya Yamanaka [Addgene plasmid # 13373] [90]). Not1 site was
added to 5’ end of STAT3-C construct by PCR, as well as BamHI cloned into 3’
terminus, following amplification the DNA was digested with BamHI and NotI. dTomato
was digested with BamHI and NotI, followed by CIP treatment. Insert and backbone
were ligated overnight and transformed in DH5α cells. Proceeded with clone 9 to make
virus after sequencing. The pWZL Neo Myr Flag MAP3K8 was a gift from William Hahn
& Jean Zhao (Addgene plasmid # 20521) [91], and was cloned into the pHIV-dTomato
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by PCR amplifying the Map3k8 with Eco1 and Xba1, ligating and transforming in Stbl3
competent cells.

Virus production
Virus was produced by transfecting low-passage 293T cells (ATCC) using
Lipofectamine (Invitrogen 2000,11668-019) and collecting supernatant over the course
of three days. Collected virus was filtered using 0.45uM filter by syringe and aliquoted in
4mL increments and frozen at -80C. To infect cells, virus was thawed prior to used and
Polybrene was added. Virus was added to cells plated in 6-well plates and centrifuged at
1200RPM for 90 minutes at room temperature. 48 hours later, successful infection could
be identified in cells expressing fluorescent markers and sorted at the UNMC Flow
Cytometry Research Facility. Antibiotic selectable markers could also be treated for at
the 48 hour time point, post infection. Puromycin would begin at 2-5ug concentration
added to media.

In vivo Bioluminescence Imaging
Expression

of

luciferase

reporters

was

analyzed

using

the

in

vivo

bioluminescence imaging system (IVIS200). Animals were injected intraperitoneally 5
minutes prior to imaging with luciferin. 1mg D-Luciferin mixed with 1mL of 2xPBS, [92],
and (Xenogen, XR-1001) and dosed at 150mg/kg of body weight. Equipped with the
IVIS200 is an XGI-8 gas anesthesia system, which was used at a 2.5% Isoflurane flow
rate (Butler Schein, 029404). Mice were anesthetized immediately prior to and during
imaging. Images were taken at 10 second to 2 minute exposure length.

Orthotopic Transplantation
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Mammary tumors were excised in sterile environment from tumor-bearing mice.
Tumors were either minced and transplanted immediately or frozen. Tissue was minced
and immediately put into Recovery Cell Culture freezing media (Gibco, 12648-010) and
stored at -80C until later transplantation. Frozen tissue used for transplant was quickly
thawed in 42’C water bath and resuspended in DMEM growth media, spun down,
resuspended again in DMEM growth media and taken for transplant. For transplantation,
0.1cm fragment was transplanted into both number four mammary glands of Athymic
nude mice, under anesthesia. Incisions were closed by staples, which were removed
after 7 days. Tumors were monitored for growth weekly using calipers.
Murine mammary tumor cell lines were harvested by trypsinization, counted,
resuspended in sterile 1xPBS and 1x105-1x106 tumor cells were injected into both
number four mammary glands of Athymic nude mice. Tumor size was monitored for
growth weekly using calipers.
Mammary gland transplants were achieved using viable frozen fragments of
target epithelium (example, BIM/BMF double knockout glands). Tissue was minced into
1 mm3 pieces and transplanted into the cleared mammary fat pad of both thoracic glands
of 21 day-old female Athymic nude mice. Tissue was permitted to engraft, forming ductal
structures, for 12 weeks. Females were bred and glands collected immediately after birth
or time points during involution.

Whole Genome RNA-Sequencing
The genome wide survey of the transcriptome was achieved by first extracting
RNA from mammary tissue or collected cell lines using the RNeasy Mini Kit (Qiagen,
74134). RNA was quantified using NanoDrop, and run on a gel to assess RNA quality.
Samples were processed using TruSeq kit (RS-122-9001DOC ). Generated cDNA was
quantified on a Qubit Flurorometer and assayed for quality control using the BioAnalyzer
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2100. Sequencing was perfomred using the HiSeq2000 (Illumina). In silico analysis was
performed on the Tusker Supercomputer (Lincoln, NE) using the Unix commands.
FASTQC (computes and provides quality profile of sequencing reads) demonstrated a
Phred score of over 32 for all samples. Tuxedo Tools (index of samtools, open source
bioconductor) were used in order to analyze the single-end reads: TopHat (uses Bowtie
for read alignment, mm10 for mouse and hg38 for human, and splice junction mapping.
Output as bam files), Cufflinks (assemble transcriptomes from RNA-Seq data and
quantifies their expression) followed by Cuffmerge (merges individual transcriptomes
into master transcriptomes, required for differential expression analysis). Cuffquant (the
output is cxb file) followed by Cuffdiff (compares expression levels of genes and
transcripts) and Cuffnorm (creates a table of normalized FPKM values).

FPKM

(Fragments Per Kilbase of transcript per Million mapped reads) values were used to
analyze the differential transcript expression between control and experimental groups.
Gene Set Enrichment Analysis (GSEA) was performed from output FPKM valued,
comparing whole gene sets or pathways. For the analysis of the control tumor cell lines
versus the Jak1 knockout cell lines GSEA permutation type parameters were set to
utilize the phenotype permutation. Analysis of the paired isogenic mammary tumor cell
lines required use of the gene_set permutation, as the program does not allow for the
phenotype permutation in a sample size less than 3 per group. Individual genes were
viewed using the Broad Institute’s Integrative Genomic Viewer (IGV).
Chromatin Immunoprecipitation Sequencing (ChIP-Seq)
ChIP seq analysis was performed for the binding of STAT3 and STAT5, using
mammary tissue from mid-pregnant females. In brief, snap-frozen tissue was
homogenized and DNA was cross-linked using 1% formaldehyde. Nuclei were isolated
in Farnham lysis buffer, samples were sonicated, centrifuged, and suspended in RIPA
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buffer. Lysate was quantified and 600-1000ug lysate were added to Dynabead antibody
complexes. Antibodies were ChIP-certified against STAT3 and STAT5. Samples were
reversed-crosslinked and was DNA purified before libraries were generated using
TruSeq ChIP sample kit (Illumina).

ChIP and Quantitative Real-time PCR (RT-PCR)
Following RNA extraction using the RNeasy Mini Kit (Qiagen, 74134),
complementary DNA (cDNA) was synthesized using Superscript cDNA synthesis kit
(protocol). ChIP was performed using primers against STAT3, STAT5, and isotypematched control IgG as described previously [58, 93]. STAT binding was assessed for
Bim and Bcl2l11 using gene-specific primers. Background and normalization was tested
using non-promoter sites as described previously [93]. Quantitative RT-PCR was carried
out using the C1000 Thermal Cycler (BioRad System, CFX96-Real Time). Conditions
and primers used listed in Table 2.2.

Statistical Analysis
Graphs and accompanying statistics were prepared using Prism 6 software
(GraphPad Software). Data computed as the mean ±SD, unless otherwise noted. The
unpaired Student t test was used to compare data sets and verifying significance. A P
value of < 0.05 was ruled significant.

Cell culture
Murine epithelial and tumor cell were maintained in the following growth media:
DMEM/F12 powder (12400-024), 10 ug/mL of Insulin (Gibco, 12585-014), 10 ng/mL
EGF (Life Technologies, E3476), 1 mg/mL BSA (Sigma, A9576), 5 ug/ML linoleic acid
complex, 50ug/mL gentamicin (Gibco, 15750-060), 0.25 units/mL fungizone (Gibco,##),
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20mg/mL FBS (Atlas, F-0500-A), 100U/mL Pen/Strep (Penicillin Streptomycin) (Gibco,
12140-122), 1.5g sodium bicarbonate (Mallinckrodt Chemicals, 7412-12), betamercaptoethanol (Gibco, 21985-023). Media was adjusted to a pH of 7.6 with NaOH and
filter sterilized using 0.22 uM filter (Millipore, SCGPS05RE). 0.05% Trypsin used for cell
passage (Gibco, 25300-054).
Generation of Primary Tumor Cell Lines
Preparation of digestion buffer:
DMEM/F12
100 units/mL pen-strep
100 ug/mL gentamicin
0.75 units/mL Fungizone
2 mg/mL collagenase
100 units/mL hyaluronidase

20 mL
200 uL
40 uL
60 uL
1 mL
300 uL

Tissue was removed by sterile means and was minced, placed in 20mL of
digestion buffer in 50mL Falcon tube, and incubated in 37C hybridization oven, rotating
speed 11 for 1-3 hours, or until dissociation was evident. Cells were centrifuged
1200RPM for 5 minutes at room temperature and supernatant removed by suction. Cells
were washed by resuspension in growth media for a total of 5 washes. Following final
wash, cells resuspended in 6mL of growth media and strained into 3 wells of 6-well plate
(2 mL each). The filter was then flipped over and washed off three times with 2mL each
growth media into the remaining 3 wells, as this captured the organoid cell clusters for
growth. Cells were maintained in 10% FBS for 6-8 weeks followed by a decrease to
5%FBS-containing growth media. During this time, fibroblast cells were removed by
partial trypsin (1mL trypsin added to a well of 6-well plate, monitored at room
temperature under light microscope, light agitation was applied to lift fibroblast-like cells.
Once lifted, trypsin removed by suction and growth media applied). Cells selected for
growth were epithelial in appearance (cobblestone structure versus spindle cells).

Generation of Murine Embryonic Fibroblasts
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Mouse embryonic fibroblasts (MEFs) were generated from Jak1-deficient
embryos at embryonic day 12.5, following the initial primary cell generation technique
described above. MEFs were cultured in DMEM, 10% FBS, 2 mM glutamine, 0.1 mM
nonessential amino acids, 10 ug mL-1 streptomycin. MEFs were immortalized by serial
passaging.

Treatment of cells
Cells were serum-starved (Growth media without FBS) for 16 hours prior to
cytokine stimulation. Treatment included: ovine GH (20nM), recombinant mouse IL-4
(50ng/mL, BD Phamingen), recombinant mouse OSM (25ng/mL, R&D Systems), LIF
(103 U/mL, Millipore), for 15 minutes at 37C, followed by cell collection. Ovine GH was a
gift by Dr. A.F. Parlow (National Hormone and Peptide Program, Harbor-UCLA Medical
Center, Torrance, CA) under sponsorship of the National Hormone and Pituitary
Program, NIDD (National Institutes of Health).

shRNA induced by Doxycyline (Dox)
Treating cells with Doxycyline hyclate (Sigma D9891-25G): stock solution was
kept at 1 mg/mL and then used at 1-2 ug/mL in cells in appropriate growth media for 48
hours.

Migration assay
Cells were trypsinized, resuspended in serum-free media, and counted using
hemacytometer. Using a 24-well plate, 1mL of serum-rich media (20% FBS) was added.
An 8 micron, insert was placed in well (8um, Corning, 353097) and desired amount of
cells resuspended in 200uL of serum-free media added (2.5x104 cells/insert) and
incubated cells for 18-24 hours. The following day migrated cells were collected and
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stained by taking the insert, washing 3 times in cold 1xPBS, and consecutively dipping
the insert 15 times each in fixative, cytoplasmic stain, and nuclear stain. The staining
was achieved using Hema 3 Stat Pack (Fisher Scientific, 123-869). The back of the
insert was wiped with a cotton swab to remove cells that did not migrate. Permount was
added to a microscope slide and the membrane insert was cut out with a razor blade
and placed in the Permount and coverslip added. Migrated cells were counted under
200x magnification the average of three field views was calculated and recorded as cells
per 1x1mm2.

Flow Cytometry Analysis
Cells were trypsinized, and washed twice in buffer (1% FBS in 1x PBS) and
counted. A total of 1x105 cells were stained for surface markers. Cells were spun down
and resuspended in 150 uL of buffer, antibody added, vortexed gently and incubated for
30 minutes on ice, protected from light. Following antibody incubated, cells were
centrifuged at 4K RPM, for 5 minutes. Cells were resuspended in 1 mL of buffer to wash,
and centrifuged, repeated twice. After the final wash, cells were strained into FACS
tubes and analyzed. Appropriate controls were used, such as unstained samples and
fluorescence controls. Flow cytometry was performed using the LSRII and analyzed
using BD FACSdiva 8.0.1 software (BD Biosciences). Antibodies used were confirmed
for flow analysis: CD61 APC Conjugate (Life technologies). OneComp eBeads
(eBioscience) used for antibody staining control.
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Target
MMTV-neu
MMTV-Cre
Jak1 fl/wt
Jak1 null
CAG-GFP
ChIP
Background
Bcl2l11 GAS #1
Bcl2l11 GAS #2
BMF GAS #1
BMF GAS #2

Table 2.2. Primer Sets for Genotyping and qRT-PCR
Lab ID Direction Sequence: 5’->3’
1259
1260
580
1785
2411
2412
2411
2372
2004
2211
2144
2145
2517
2519
2520
2521
2512
2513
2514
2515

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

TTTCCTGCAGCAGCCTACGC
CGGAAC CCACATCAGGCC
GATGTGAGACAAGTGGTTTCCTGAC
CATCACTCGTTGCATCGACC
GAGACAGGATACCTGGTGGCTTGG
GTAGCAGTCCTGGACATTGAGTCC
GAGACAGGATACCTGGTGGCTTGG
AGGTGCCACTCCCACTGTCCTTTCC
GGCTCTAGAGCCTCTGCTAACC
GCCATTGGGATATATCAACGGTG
GGCCACTCATCAGCTCTCACCCATAC
GCTCTCTCAAGCCTCCAGCAAAAACC
GCGACGAAGAATCTCGCTTGAGGCGC
GTGTTTACCCTAGTGTCTTGGCCTG
ATCAGTGAAAGTTAGTTCTCTGCCTTC
CACAGATTTACCTACAGGCAACCTGAT
CCAGTCCTCTATAAAGTAATTCCTTGG
CAGGTAGATTCAGGTCAGATTGCAGAG
CTGGCTCTGTTTATATCACTCGCTATA
CCAGCCACTTTTCTTTATTCTTTCTTT

PCR Conditions
Step 1: 96C, 3 min
Step 2: 96C, 1 min.
Step 3: 60C, 1 min
Step 4: 72C, 1 min
(to Step 2, 32x)
Step 5: 72C, 5 min
Step 6: 4C, pause

Step 1: 95C, 3 min.
Step 2: 95C , 30 sec.
Step 3: 60C, 30 sec.
Step 4: 70C, 30 sec.
(to Step 2, 39x)
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Table 2.3. Antibodies for Immunoblotting and Immunostaining
Target
Source
Catalog #
Application
STAT1
pY-STAT1
pS-STAT1
STAT3
pY-STAT3
STAT5
pY-STAT5
STAT6
pY-STAT6
GAPDH
b- ACTIN
pTyr
c-FOS
RUNX1
BMF
BIM
JAK1
JAK2
WFDC5
E-Cadherin
GFP
CK8
CD14
OSMR
BCL3
TUBULIN
PDGFRA
SOCS1
SOCS3

Santa Cruz
Origene
Abcam
Cell Signaling
Cell Signaling
Santa Cruz
Cell Signaling
Santa Cruz
Abcam
Cell Signaling
Santa Cruz
Cell Signaling
Abcam
Origene
Enzo
Abcam
Dr. Hallgeir Rui
Cell Signaling
LifeSpan
BD
Aves
Laboratories
Iowa Hybridoma
Bank
Abcam
Santa Cruz
Biossuas
Epitomics
Boster
Boster
Santa Cruz

SC-592
TA309955
Ab109461
9139S
9145S
SC-836
9351S
SC-981
Ab54461
5174
I-19
05-321
Ab7963
TA309955
17C2
Ab7888
(Gift)
3229
LS-C297015
610181

WB
WB, IHC
WB
WB
WB, IHC
WB
WB, IHC
WB
WB
WB
WB
WB
WB, IF
WB, IF
WB
WB
WB
WB
WB
IF

GFP-1020

WB, IF

Troma-1

IF

Ab182032
SC-8494
Bs-6591R
1878-1
PB9771
PA1074
SC-9023

IF
WB
IF
WB
IF
IF
WB, IF
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Chapter 3: Janus kinase 1 mediates inflammatory cytokine signaling during
mammary gland involution
Experiments published: *Sakamoto, K.; *B.L. Wehde; K.H. Yoo; T. Kim; N. Rajbhandari;
H.Y. Shin; A.A. Triplett; P.D. Rädler; F. Schuler; A. Villunger; K. Kang; L. Hennighausen
and K.-U. Wagner (2016): Janus kinase 1 is essential for inflammatory cytokine signaling
and mammary gland remodeling.
Mol. Cell. Biol. 36 (11): 1673-1690
*Contributed equally
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Introduction
The postnatal growth and development of the mammary gland is dependent on
hormones, growth factors, and locally derived cytokines to induce ductal elongation and
branching, functional differentiation of the epithelium, and the postlactational remodeling
of the gland. Initially, estrogen serves to induce ductal elongation after puberty.
Meanwhile, during pregnancy and nursing offspring progesterone and prolactin (PRL)
promote the functional differentiation, proliferation, and maintain cell-sustaining signals.
Following weaning of the offspring, a decrease in the circulating levels of prolactin along
with milk stasis initiate the local production of interleukin-6 (IL-6)-class cytokines.
Notably, Oncostatin M (OSM) and leukemia inhibitory factor (LIF) are the prominent
members of the IL-6 class that initiate the cascade of intracellular events that culminate
in the programmed cell death and removal of select terminally differentiated epithelium.
The ligands such as PRL and OSM rely on nonreceptor associated Janus
kinases

to

activate

their

corresponding

receptor,

mediating

the

signal

and

phosphorylating subsequent signal transducers and activators of transcription (STATs).
Activated STATs function to bind to the DNA, altering the transcriptional profile and
molecular events of the cells. In the family of seven STAT members (STAT1, 2, 3, 4, 5a,
5b, and 6), five are expressed within the mammary epithelium (STATs 1,3, 5a/b, and 6),
although they are activated a defined stages of mammary gland development. While
STAT1 and STAT6 play subordinate role in development, the effects of STAT5 and
STAT3 are robust. During pregnancy and lactation, STAT5 responds to the increase of
PRL, and through its activation by JAK2, drives the transcription of genes associated
with proliferation and differentiation. Contrasting the cell-sustaining signals, the drastic
physiological event of involution is characterized by a decrease in STAT5 activation and
surge in the phosphorylation of STAT3. In response to the cytokines LIF and OSM,

52

STAT3 is driven to the nucleus and upregulates genes associated with matrix
remodeling and apoptosis.
The contribution of STATs to mammary gland development has been well
studied, although curiously, little has been investigated on their upstream Janus kinase
activators. In the family of four Janus kinases, two are expressed within the mammary
epithelium as JAK3 and Tyk2 are primarily restricted to the hematopoietic system while
JAK1 and JAK2 have increased ubiquitous expression. The functional role of JAK2 in
the mammary gland has been established through the development of conditional
knockouts, demonstrating its crucial role in mediating signaling of PRL to activate STAT5
for alveologenesis as well as differentiation of the mammary epithelium. Conversely, the
role of JAK1 has not been addressed in adult organ development, and specifically, the
STATs activated during mammary gland development and sequential STAT activation is
unknown.
We demonstrate, for the first time, the analysis of a conditional deletion of JAK1
in a mammary –specific manner. The results support a nonredundant role for JAK1 in
activating STAT1, 3, and 6, and demonstrate the biologically relevant role for JAK1 in
coupling extracellular cytokines to cell death machinery the differentiated mammary
epithelium.

Results
JAK1 expression levels in the virgin and pregnant female mammary gland parallel
with phosphorylation of STAT1 and STAT6 as well as STAT3 activation during
involution.
Previous studies have explored the biological significance of five of the seven
STAT proteins (STAT1, STAT3, STAT5a, STAT5b, and STAT6) during mammary gland
development. To identify changes in STAT activation in the context of JAK1 expression
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in the mammary gland, we followed protein expression and activation status of the five
STATs along with JAK1 throughout a complete postnatal development cycle. Mammary
tissues from virgin glands, several time points during pregnancy, lactation, and involution
(i.e., day 2 post-weaning) were analyzed by immunoblot (Fig. 3.1A). While all of the
STATs are expressed at nearly consistent levels throughout the development cycle, as
indicated by total protein levels, their various windows of activation may suggest differing
upstream activators. STAT1 phosphorylation is prominent during virgin state and early to
mid-pregnancy before declining during lactation and remaining low during involution.
Active STAT6 displayed low levels throughout the whole development cycle, declining
during involution. STAT5 was robustly phosphorylated during mid-pregnancy and
lactation, and decline sharply at the onset of involution. In near-contrast, active STAT3
was observed during pregnancy, decreased during late pregnancy and lactation, but
prominently increased during involution. The expression of JAK1 was seen during virgin
and stages of pregnancy, and mirroring STAT3 activation, also fell during late pregnancy
and lactation yet increased during involution. The STATs demonstrate activity during
mid-pregnancy, although the activation of STAT1 and STAT6 follow the expression of
JAK1 during the virgin stage and pregnancy, as well as STAT3 activation coinciding with
JAK1 expression during involution event.

JAK1 mediates cytokine signaling to activate STAT1, STAT3, and STAT6 but not
STAT5 in embryonic fibroblasts in the mammary gland epithelium.
In order to investigate the biologically relevant functions of JAK1 during postnatal
and adult development, we used the previously described conditional knockout model for
Jak1 [82]. In summary, the gene-targeted Cre/lox-based system inserted loxP sites
upstream and downstream of the second coding exon of Jak1, and employed a
neomycin selection marker in intron 3 which did not cause phenotypic abnormalities in
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homozygous mice. Resulting

Jak1fl/fl

mice were comparable and indistinguishable to wild

type controls (Jak1+/+). To validate the null allele during embryogenesis, the Jak1 fl/fl was
recombined in the female germ line. The resulting deletion of Jak1 led to perinatal
lethality in newborn homozygous mice. Embryonic murine fibroblasts were derived from
homozygous JAK1-knockout embryos at embryonic day 12.5 as well as from
heterozygous embryos and wild type controls, to assess STAT activation. The deletion
of the Jak1 second coding exon causes a frameshift of the coding sequence and results
in the absence of the JAK1 protein without a compensatory upregulation by JAK2 (Fig.
3.1B). In the absence of JAK1, cells displayed a drastic decrease in the tyrosine
activation of STAT1 and STAT3, although STAT1 serine phosphorylation on S727 was
preserved, indicating that the two events may occur independently of each other.
Stimulation of cells by IL-4 and GH demonstrated that STAT6 relies on JAK1 for IL-4induced signaling, conversely STAT5 activation by growth hormone stimulation was
unperturbed by a loss of JAK1 (Fig. 3.1C).
For the analysis of JAK1 specifically in the mammary gland, a cohort of female
mice were generated carrying the MMTV-Cre transgene in a Jak1-floxed homozygous
background. Littermate controls carried the homozygous Jak1, but lacked Cre
recombinase. Mammary glands from the experimental and control group were compared
at gestation day 14.5, a point where all STAT proteins exhibit various activity (Fig. 3.1A).
The architecture of the glands were similar and a Jak1 deficiency appeared to have little
effect on alveoli differentiation. Although, analysis by immunohistochemistry indicated a
loss of pSTAT3 activity in the epithelial compartment, meanwhile active tyrosinephosphorylated STAT5 was unaffected (Fig. 3.1D). To understand the activation of
STAT1, STAT3, and STAT6, mammary epithelial organoids were freshly prepared and
treated for 20 minutes with OSM and IL-4 (Fig. 3.1E). Similar to the initial studies in
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fibroblasts, an absence of Jak1 uncoupled ligands from downstream mediators, STAT1,
STAT3, and STAT6.

A deficiency in JAK1 leads to impaired postlactational mammary gland
remodeling.
To reveal the biological functions of JAK1 throughout mammogenesis, we
examined the composition and morphology of mammary glands from tissue of JAK1
conditional knockout females and controls during a complete gestation cycle. A GFPbased reporter transgene for Cre recombinase demonstrated that deletion of Jak1 by
MMTV-Cre occurred throughout the ductal system (Fig. 3.2A) and indicated no negative
selection prior to pregnancy. Deficiency of JAK1 also had no effect on ductal elongation
or branching. Even though JAK1 contributes to the activation of STAT6, which is
implicated in alveologenesis, no defects were observed during pregnancy. Experimental
females were also able to lactate effectively compared to controls, supporting offspring
until weaning. Histologically, the glands during lactation were similar between the two
groups (Fig. 3.2B, left) and there was no remarkable differane at 24 hours post-weaning
(Fig. 3.2B, middle). Strikingly, JAK1-defienct females displayed a pronounced delay in
postlactational remodeling at 3 days post-weaning (Fig. 3.2B, right) and extended into
day 5 of the remodeling process (Fig. 3.2C, left). The impairment of effective remodeling
was also confirmed in a second mammary-specific model, WAP-Cre, for the deletion of
Jak1 (Fig. 3.2C, right), where recombination of the target gene occurs in differentiated
alveolar cells during late pregnancy and lactation.
Deletion of JAK1 uncouples gp130-mediated signaling though IL-6-class cytokine
receptor complexes from its downstream effector, STAT3.
The most dramatic switch in tyrosine phosphorylation of STAT3 and STAT5
occurs between the physiology events of lactation and involution (Fig. 3.1A). To confirm,
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immunostaining was performed demonstrating the high levels of nuclear STAT5 in the
lactating glands, present in both control and JAK1-knockout female mice, which then
decreased 24 hours into the remodeling phase (FIG. 3.3A). Although few, noticeable
pSTAT5 staining was observed in the nucleus of JAK1-deficient glands within the first 24
hours of involution. In contrast to the strong nuclear STAT5 staining, nuclear
accumulation of tyrosine-phosphorylated STAT3 was dramatically decreased in the
JAK1-knockout female glands in the initial stages of involution. This striking molecular
phenotype along with our previous observations that the expression of JAK1 is
increased during the onset of involution, suggests that JAK1 plays a crucial role in
mediating the signaling events necessary for remodeling and activation of STAT3 in the
mammary gland.
The two IL-6 class inflammatory cytokines that initiate the signaling of remodeling
events in the mammary gland signal through specific ligand-receptor complexes that
share the glycoprotein 130 (gp130) signal transduction unit, culminating in the activation
of STAT3 for the involution of the mammary gland. To assess the importance of JAK1 as
a mediator of signaling through gp130, wild type embryonic fibroblasts along with those
hetero or homozygous Jak1-deficient were treated with OSM and LIF. The activation of
STAT1 and STAT3 were tested for activation and the results by immunoblot
demonstrate the prominent role of JAK1 for mediating the IL-6-class ligands, as a lack of
JAK1 uncouples the activation of STAT1 and STAT3 from the inflammatory cytokines
(Fig. 3.3B). To translate the in vitro data to the mammary gland, virgin female mice were
injected with both OSM and LIF before gland were collected and analyzed by
immunofluorescent staining of pSTAT3 (Fig. 3.3C). The strong staining in the wild type
glands of OSM and LIF indicate active STAT3 being driven to the nucleus, as well as a
presence in the surround stroma (Fig. 3.3C, left). Conversely, JAK1-deficient females
treated with cytokines have a failure of active and nuclear STAT3, although
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phosphorylated STAT3 is evident in the stroma of the knockout female glands (Fig.
3.3C, right). The active STAT3 in the surrounding stroma serves as an internal positive
control, wild type in JAK1, as the Cre recombinase is only active within the mammary
epithelium. Both the studies in JAK1-deficient fibroblasts and mammary gland-specific
deletion indicate that Janus kinase 1 is the dominant tyrosine kinase to mediate
signaling through gp130-recpetor complexes in response to inflammatory cytokines.

Ablation of Jak1 produced deregulated expression of downstream target genes
associated with the acute-phase response, inflammation, wound healing, and
programmed cell death.
To further explore the downstream effect and mechanism that a Jak1-deficiency
causes in mammary gland remodeling, we performed genome-wide RNA-Seq analysis
comparing tissue from lactating glands to involuting mammary tissue lacking JAK1 and
wild-type controls. First, we focused on comparing wild-type lactating mammary gland
tissue to the involuting mammary gland, observing the genes and pathways are
upregulated during the remodeling phase. Next, we concentrated on identifying genes
that demonstrated a lack of normal expression during involution with an absence of
JAK1. The initial comparison between three wild-type lactating and involuting mice
revealed that 1.131 genes had a 2-fold or higher upregulation during involution and
1,378

genes

were

downregulated.

Supporting

the

phenotype

and

stage

of

mammogenesis, a distinct reduction in expression of genes linked to proliferation and
cell survival signaling driven by JAK2/STAT5 coincided with an increased expression of
genes associated with inflammatory signaling. The known targets of PRL and
JAK2/STAT5 signaling such Socs2, Ccnd1, Akt1 were downregulated in the involution
tissue, while an increased expression of Lif, Osmr, Stat3, and Socs3 was seen. The
cytokine receptor switch between the two phases of lactation and involution, as well as a
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synchronous exchange of the JAK/STAT pathway are illustrated by gene set enrichment
analyses (GSEAs) of the RNA-Seq datasets (Fig. 3.4A). We also observed an increased
expression of transforming growth factor B signaling and apoptosis during involution, as
well as deregulated expression of NF-kB signaling and upregulated expression of the
tumor necrosis factor receptor superfamily, particularly Tnfrsf1A, Tnfrsf10B, and
Tnfrsf21.
To identify the genes deregulated during involution in a JAK1-dependant manner,
the gene expression profiles for four conditional knockout mice were compared with
three wild-type controls at the second day of involution. Only 135 genes displayed a 2fold or more deregulation expression, while 203 genes resulted in an increased
expression. Consistent with what we observe at the protein level, genes that
demonstrated deregulation in JAK1-deficient glands include Stat3 itself, as well as
known STAT3 targets such as Socs3, Osmr, and Bcl3 (Fig. 3.4B). Also consistent with
the STAT3-deficient mice [63], we observe a reduced expression in genes associated
with inflammation, acute-phase response (Cd14, Saa1/2, and Lrg1) and wound healing
(Chi3L1). Together with the known targets of STAT3, we found Runx1 and c-Fos to be
deregulated, as a lack of increased expression was seen compared to their dramatic rise
observed in the involution tissue. A new JAK1-dependant milk protein was also found,
the WAP four-disulfide core domain protein (Wfdc5), which was found upregulated
during involution and is unlike the milk protein WAP that decreases over the same time,
Interestingly we also discovered several JAK1-dependant genes that regulate cell
survival and apoptosis. Their downregulation could be responsible for the lack of
remodeling cell death in the mammary epithelium. These candidate genes include the
death receptor 6 gene (Tnfsf21) and the tumor susceptibility gene Tpl2 (Map3k8).
Although, the most consistently deregulated proapoptotic factor was, Bmf, a gene
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encoding for the Bcl2-modifying factor and BH3-only protein. Related to BMF, the gene
Bim (Bcl2l11) and Bid were also found downregulated.
The RNA-Seq analysis was complete with the addition of three expression
libraries of lactating JAK1-knockout mammary glands. The remarkable precision of RNASeq allowed us to view the expression of individual exons of genes, notably, Jak1. In all
sets of tissue, in the sample comparison of experimental and control groups during
lactation and involution, we were able to precisely identify the excision of the second
coding exon in the experimental tissue (Fig. 3.5, top). We noted an increase in Jak1
expression levels throughout the involution tissues, which correlates to the increased
JAK1 protein levels tested at the same developmental window (Fig. 3.1A). JAK1 had no
effect on JAK2/STAT5-responsive genes, such as beta-casein (Csn2) (Fig.3.5, middle).
Observing the STAT3 target genes such as Cd14 and c-Fos, their transcriptional levels
were remarkable decreased, as were the newly identified proapoptotic genes, Bmf and
Bim. Although both genes displayed over 2-fold deregulated expression, Bmf had 4-fold
higher expression profile in wild-type tissue overall (Fig. 3.5, lower). Similar to the
previous report of the upregulation of Pik3r1, the p50/55 isoforms of the
phosphatidylinositol 3-kinase (PI3 kinase), we found that Runx1 was selectively
expressed from an intronic promoter that encodes the shorter isoform 3. This finding
exemplifies the fidelity of RNA-Seq technology but also demonstrates the importance of
using appropriate antibodies that recognize various isoforms at the protein level.
Confirmation of the newly identified JAK1 targets was done by immunoblot,
Supporting the earlier findings that JAK1 had no effect on the activation of STAT5 during
lactation, phosphorylated STAT5 was consistent in wild-type and knockout lactation
tissue (Fig. 3.6A). Analysis of STAT3 confirmed upregulation of active STAT3 at the
onset of involution throughout control samples, but was significantly reduced in the
involution tissue of the knockout. The targets identified by RNA-Seq, RUNX1, BMF, BIM,
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and WFDC5 also demonstrated reduced protein expression. Both RUNX1 and c-FOS
have known expression in the hematopoietic system and immunostaining of these
targets on histological sections of control and JAK1-deficient tissues demonstrate that
they are indeed upregulated during involution, but their expression depends on JAK1
(Fig. 3.6B and C).

BMF and BIM are downstream targets of JAK1, and their combined deficiency
phenocopies an impairment of mammary gland remodeling similar to JAK1deficient mice.
The analysis of the mRNA profiles of lactating and involuting mammary tissues
show that several genes of the Bcl2 family members display notable changes in their
expression. We observed not only more than a 2-fold upregulation of Bax, Bcl-x (Bcl2l1),
Bmf, Bim (Bcl2l11), and Bid, but a 3 and 7-fold upregulation of Bbc3 (Puma) and Bik
(Fig. 3.4). A more than 2-fold downregulation of prosurvial factor Bcl-w (Bcl2l2) was also
seen during involution (not shown). The most significantly downregulated Bcl2 family
member was Bmf, along with Bim. In order to identify whether these two genes were
preferentially bound by either STAT5 or STAT3, we performed preliminary analysis of
the ChIP-Seq data sets from female glands during mid-pregnancy, a time point that
represents when all STAT proteins that are expressed in the gland are active at various
levels (Fig. 3.7). Socs2 and Socs3 served as preferential binding controls for STAT5 and
STAT3, respectively. We observed a strong preference for STAT3 binding sites near
Osmr, Bcl3, and Stat3, which is depicted in the histograms (Fig. 3.7). STAT3 was also
showed enrichment in binding near Bmf and Bim. To quantify the binding of STAT3 of
both Bmf and Bim, during the development phases of lactation and involution, we
performed ChIP followed by quantitative reverse transcription-PCR (qRT-PCR) for
canonical gamma interferon activation sites (GAS). We found that STAT3 occupied GAS
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sequences near transcriptional start sites of both genes, and that the binding of DNA
was greatly increased during involution (Fig. 3.8). The combined results of the ChIP-Seq
and qRT-PCR data further suggest that STAT3 promotes the transcription of these proapoptotic family members during involution.
As Bmf and Bim appear to be downstream targets of JAK1/STAT3 signaling we
anticipated that a functional loss of Bmf alone or in combination with Bim may
phenocopy the delayed involution signature of the JAK1 conditional knockout mice. To
answer this question we examined the histology of lactating and involuting glands of
BMF- and BIM-single-knockout mice. Similar to the JAK1-knockout phenotype, the
functional loss of either protein did not affect lactating tissue, although, we saw a delay
in the remodeling process in both mutant tissue, with the observation being more
pronounced in the BMF-deficient glands (Fig. 3.9). These phenotypic observations of the
BH3-only family members provide evidence for their functional role for initiation
apoptosis in differentiated mammary epithelial cells. Based on our data comparing
lactation tissue to involution, where the two proteins are upregulated during involution in
tandem, we hypothesized that they might act synergistically during the remodeling
phase. Experimentally, we addressed this question by transplanting BMF/BIM-doubleknockout tissue into the cleared mammary fat pad of wild-type recipient female mice.
Tissue engraftment was successful and following ductal outgrowth after 12 weeks posttransplantation, recipient mice were bred and mammary glands were collected
immediately following birth of offspring (Fig. 3.10, postpartum). Similar to a deficiency in
a single gene, the double knockout tissue was indistinguishable from that of wild-type
glands during lactation. However, we saw a striking delay in the remodeling process of
the double-knout tissue (Fig. 3.10, involution). Histological analysis of active STAT3 in
BIM- and BMF-single and double knockout mice demonstrate a clear and strong nuclear
stain for the transcription factor, and was comparable to the wild-type involution tissue
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(Fig. 3.10). Because the recipient mice are wild-type for JAK1, it is evident that these
proteins act in a cell-autonomous manner. These results suggest that both proapoptotic
family members have a significant role in the remodeling process and biologically
function downstream of JAK1 and STAT3.

Fig. 3.1.
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Fig. 3.1. JAK1 is essential for the activation of STAT1, STAT3, and STAT6 in
embryonic fibroblasts and mammary epithelial cells. (A) Immunoblot analysis of the
expression of JAK1 and tyrosine phosphorylation of STAT1, STAT3, STAT5 and STAT6
during mammary gland development. (P numbers indicate day of pregnancy; L7,
lactation day 7; I2, involution day 2). The individual panels represent immunoblots of
tissues from different mice. (B) Expression of JAK1 and JAK2 as well as steady-state
activation of STAT1 and STAT3 in primary mouse embryonic fibroblasts (MEFs) from
heterozygous and homozygous JAK1-knockout embryos which were generated through
germ line deletion of the floxed locus (Jak1=/- [+/-] and Jak1-/- [-/-], respectively) as well
as MEFs from wild-type controls (Jak1=/= [+/+]). (C) IP/Western blot analysis of STAT5
and STAT6 in GH- and IL-4-treated wild-type and JAK1-knockout MEFs. (D)
Immunohistochemical staining of active STAT5 and STAT3 on mammary tissue sections
from a JAK1 conditional knockout mouse (MMTV-Cre Jak1flox.flox [MCre Jak1fl/fl] and a
littermate wild-type control (Jak1flos/flox[Jak1fl/fl] at day 14.5 of gestation. The slides were
counterstained with hematoxylin. Bar, 50 μm. (E) Western blot analysis of
phosphorylated STAT1, STAT3, and STAT6 in explanted mammary epithelial organoids
from mice with mammary gland-specific JAK1 knockout and their wild-type controls with
and without treatment with OSM and IL-4.
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Fig. 3.2.
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Fig. 3.2. The biologically relevant function of JAK1 is restricted to the remodeling
phase. (A) (Top) Fluorescence images using the GFP-based reporter for recombination
in wild-type (left) (MMTV-Cre Jak1flox/+ CAG-LSL-GFP) and JAK1-knockout (right)
(MMTV-Cre Jak1flox/flox CAG-LSL-GFP) nulliparous mammary glands. Whole mount
images of control and knockout mammary glands fixed and stained by carmine alum,
display similar ductal architecture (Lower). (B) H&E-staining of sectioned mammary
glands from control and JAK1-deficient experimental females at the timepoints of
lactation (left) and two involution timepoints (right). Bars,100 μm. (C) Whole mount
analysis comparing the MMTV-Cre deletion of Jak1, and the WAP-Cre-mediated
excision of Jak1, along with wild-type controls, each as involution day 5. Bars, 2 mm. LN,
lymph node.
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Fig. 3.3.
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Fig. 3.3. Analysis of STAT activation in the mammary gland and embryonic
fibroblasts in response to cytokines OSM and LIF. (A) Immunostaining of tyrosine
phosphorylated STAT3 and STAT5 in the wild-type and conditional JAK1-knockout
mouse mammary gland during lactation and involution. Bar, 50 μm. (B) Western blot
analysis of tyrosine-phosphorylated STAT1 and STAT3 in embryonic fibroblasts wildtype, heterozygous, or homozygous-deficient in Jak1, in response in LIF and OSM
treatment. (C) Nulliparous mammary glands from wild-type and JAK1-knockout females
after treatment with exogenous OSM and LIF. Bars, 50 μm.
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Fig. 3.4.
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Fig. 3.4. Comparison of the gene expression between normal lactation and
involuting glands, and identification of genes deregulated in a JAK1-dependent
manner during remodeling. (A) Gene set enrichment plots with heat maps of genes
that are selectively upregulated during the second day of involution compared to their
status in lactation. (B) Heat maps of selected genes that are upregulated during
remodeling but experience a 2-fold or more downregulation in the JAK1-deficient gland.
Both control and JAK1-knockout tissue were from the second day of involution.
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Fig.3.5.
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Fig. 3.5. Janus kinase 1 is necessary for the expression of STAT3 target genes
and newly-identified JAK1-dependent genes. The individual histograms depicting the
RNA-Seq data from wild-type and JAK1-knockout glands during lactation and involution,
depict the expression levels of the identified genes as well as their exon usage. (Upper)
the box highlighting the exon 2 of Jak1 indicates the deletion of the exon in the knockout
samples. (Middle) the milk protein gene Csn2, serves a control for a STAT5-responsive
target that is downregulated during involution. Cd14 and Pik3r1 provide controls for
STAT3 targets known to increase during involution under normal conditions, and whose
expression is reverted in the knockout glands. C-Fos, Bmf, Bim, and Runx1 are newly
identified targets of JAK1 signaling.
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Fig. 3.6.
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Fig. 3.6. Confirmation of target gene protein expression in wild type tissue and
JAK1-deficient tissue by Western blot and immunofluorescent staining. (A)
Western blot analysis of control and knockout tissue during lactation and involution
depict a decrease in the target proteins RUNX1, BMF, BIM, WFDC5. (B and C)
Immunofluorescence of the target genes RUNX1 and c-FOS on lactation day 9 tissue
and involution day 2, with E-cadherin (CDH1) and DAPI served as counterstain. Bars, 50
um. (C) Inset panel demonstrates closer view of tissue lacking c-FOS expression
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Fig. 3.7.
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Fig. 3.7. STAT3 and STAT5 demonstrate various binding affinities for downstream
target genes. The individual panels display the histogram of ChIP-Seq data sets for
select target genes, and portrays the transcription factor binding in midpregnant glands.
Socs2 and Socs3 serve as binding controls for STAT5 and STAT3, respectively. STAT3
has prominent binding near sites of Osmr, Bcl3, and Stat3 itself. The newly identified
targets, Bmf and Bim display higher affinity for STAT3 binding in proximity to these loci
(boxes indicate canonical STAT recognition sites [TTCN3GAA] referred to in Fig.3.8.)
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Fig. 3.8.
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Fig. 3.8. qRT-PCR from ChIP by STAT3 and STAT5 demonstrates the binding of
STAT3 and STAT5 to target genes during lactation and involution. Schematic
outline of the location of canonical STAT binding sites near or within the genes encoding
for BH3-only proteins BMF (A) and BIM (B). Boxes indicate the location of exons, and
numbers refer to exon number. Bar graphs demonstrate results of quantitative real-time
PCR from DNA isolated by ChIP in lactation day 7 and involution day 2 mammary tissue
with antibodies directed against STAT3, STAT5, and IgG control. Primer sets used to
amplify select regions surrounding STAT-binding sites are specific for sequences
located within the 5’ intragenic regions of BMF and Bim. Values were normalized against
primers sets for nonconsensous binding sites. Bars represent means and SDs, **,
P<0.01.
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Fig. 3.9.
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Fig. 3.9. The remodeling events are delayed in mice that genetically lack BMF or
BIM. The H&E staining was performed on tissue collected from mice during lactation and
involution from mice wild-type for both genes (BMF+/+ Bim+/+), lacking only BMF (Bmf

-/-

Bim +/+) or deficient in only BIM (Bmf+/+ Bim-/-). Bars, 100 μm.
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Fig. 3.10.
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Fig.3.10. Double knockout mice for BMF and BIM display impaired remodeling.
Whole mount analysis reveals that while wild-type mice progress through normal
involution (left panel) the recipient mice of the double knockout tissue have a notable
delay in the involution process (middle, right). Tissue was collected after birth of
offspring and four days after weaning. Immunohistochemical staining of the wild-type
and double knockout tissue for phosphor-tyrosine STAT3 indicate strong nuclear
localization. Bars, 50 μm.
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Discussion
The biologically essential functions of JAK1 are restricted to the events of
postlactational remodeling of the mammary gland.
Through the extensive characterization of STAT proteins and their activity in the
JAK1 conditional knockout mouse model, it was shown that JAK1 contributed to the
cytokine-induced tyrosine phosphorylation of STAT1, STAT3, and STAT6, not only by
cell culture in embryonic fibroblasts but in the developing female mammary gland.
Although JAK1 was responsible for the activation of three STAT family members, the
phenotypic consequence for the lack of JAK1 in a developing gland was largely
restricted to the postlactational remodeling phase where there was a failure of the gland
to respond to the acute rise in inflammatory cytokines. This delay in remodeling
resembles the phenotype of STAT3-deficient glands, as well as models that lack gp130
or IL-6 [49, 67]. The loss in activation of STAT1 and STAT6 within the mammary
epithelium did not impede growth or development of the gland. Previous reports are
indicate that STAT1 is dispensable for ductal elongation and alveologenesis and that the
role of STAT1 in mediating optimal ductal branching is dependent on active STAT1 in
the stroma [54]. A STAT6 deficiency has been shown to impair mammary alveolar
development during early pregnancy, a phenotype that was observed to be repaired
during later stages of gestation with no defects noted during lactation. The rebound of
the gland during stages in pregnancy could be due to a paracrine effect of STAT6 in the
stroma inducing mammary epithelial proliferation [55]. This may explain why a JAK1deficiency in the mammary gland does not phenotypically compare with a STAT6knockout model.

The Janus kinase 1 and 2 may have nonredundant roles in the activation of STAT
proteins during mammary gland development.
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Previous work investigating JAK2 in the mammary gland describes the kinase to
specifically activate STAT5 in the mammary gland compartment, in response to PRL
signaling. The mammary-specific deletion of JAK2 resulted in the impaired development
and growth of alveolar cells, and no compensation by another kinase or downstream
mediators of the JAK2/STAT5 pathway was observed to rescue the phenotype [60].
Strikingly similar, the loss of JAK1 in the developing mammary gland had no effect on
the activity of STAT5, and in the involution events, and the loss of response to
inflammatory cytokine signaling, no other kinase was able to effectively compensate for
the genetic lack of JAK1 and subsequent STAT3 activation. The collective findings of
each in each of these studies indicate that JAK1 or JAK2 is not able to compensate for
the loss of the other to activate STAT5 or STAT3 in the same cell type, in response to
ligand-receptor signaling (Fig. 3.11). Observations built from the biological and molecular
phenotype support the idea that there may be no functional overlap between the kinases
during normal gland development. The impact of this premise could be far-reaching as
there are man reports that state JAK1 and JAK2 are capable of phosphorylating STAT3,
in response to inflammatory cytokine signaling in vitro. It has been observed in initial
studies that JAK1 mediates IL-6 signaling [94-97], yet current work has displayed JAK2
as the key mediator for STAT3 activation in the disease setting [98-101]. This could
largely be due to the use of pharmacological inhibitors that are labeled as “JAK2
inhibitors”, when in they actually may inhibit both JAK1 and JAK2 with near similar
kinetics [102]. A strong argument again the role of JAK2 activating STAT3 is displayed in
recent work, where a genetic deletion of JAK2 in mammary cancers still display
constitutive STAT3 activation [80]. Furthermore, STAT3 signaling in malignancies has
been shown to depend on IL-6 autocrine signaling [103-106], initiated by receptor
tyrosine kinases. We have demonstrated that JAK1 is essential for gp130-mediated
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signaling, and that this kinase and not JAK2 may be crucial for targeting the persistent
activation of STAT3 in disease.

JAK1 is a crucial mediator of IL-6-class inflammatory cytokine signaling and
activating

downstream

cell

death

complexes

in

differentiated

mammary

epithelium.
The collective findings provide rational that JAK1 maintains a crucial function
during the involution phase of mammary gland development. The expression levels of
JAK1 were observed to rise during the involution time points by protein analysis and
validated at the transcriptional level by RNA-Seq. The deletion of this kinase closely
mirrored the biological consequences seen in STAT3-, gp130-, or IL-6-deficient mice
[36, 49, 67]. The functional loss of JAK1 uncoupled inflammatory cytokine signals from
their downstream effector STAT3, which led to a deregulated expression of STAT3
target genes during this biology time point. The genome-wide investigation of genes
selectively upregulated druing involution in a JAK1-dependant manner revealed known
STAT3 targets such as Osmr, Cd14, and STAT3 itself, as well as targets such as c-Fos,
a proto-oncogene known for its regulation in tissue remodeling by regulation of
metalloproteinases [107-109]. Other targets included Tpl2 (Map3k8), and death receptor
6 (Tnfsf21), although their functions have not been explored. The function of JAK1 in
coupling cytokine signaling to crucial mediators of mitochondria-associated cell death
machinery was found in its regulation of the BH3-only protein BMF and BIM. Single
knockouts of each BMF and BIM confirm their role in aiding in remodeling, and
synergistically, a double knockout of both proteins dramatically delays remodeling [110].
This phenotype corresponds to the knockout JAK1, where upending JAK1 deregulated
both BMF and BIM in the mammary epithelium. Corroborating data from the RNA-Seq
analysis and qRT-PCR demonstrate that STAT3 binds in close proximity to these genes.
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Although, the STAT3-deficient knockout did not show similar deregulation, suggesting
that other transcription factors whose expression level depend on JAK1 also contribute
to the regulation of Bmf and Bim, or that STAT5 may function a suppressor or Bim [111].
Although, the nuclear localization of active STAT3 is unchanged from wild-type mice to
knockouts of BMF and BIM, which supports that these two factors function downstream
of STAT3. While the lysosome-mediated pathway, driven by STAT3, an alternative
model for remodeling in the mammary gland [111], its activity was not able to offset the
inhibited canonical apoptotic pathway. The conditional knockout model of JAK1 in the
mammary gland led to impaired remodeling and downstream targets of JAK1/STAT3
signaling were verified on a genome-wide scale and confirmed at the protein level and
validated in genetic in vivo knockouts, demonstrating that this kinase is essential for
driving involution in response to inflammatory cytokine signaling.
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Fig. 3.11.

Fig. 3.11. JAK1 and JAK2 display nonredundant functions and activate
specific STAT proteins in mammary epithelial cells. JAK2 mediates the signal
of PRL to activate STAT5 during lactation. The switch to involution requires JAK1
to activate STAT3 downstream of inflammatory cytokines OSM and LIF during
involution.
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Chapter 4: JAK1 is crucial for persistent STAT3 activation in mammary
tumors
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Introduction
The results of the previous chapter clearly illustrate that JAK1 is the essential
mediator for the inflammatory signaling in the mammary gland [86]. The Cre/lox system,
under control of the MMTV promoter, specified the deletion of Jak1 to the mammary
gland and avoided perinatal lethality [20].

As the MMTV promoter is active during

development, the mice were monitored from birth to pregnancy and through involution.
Most striking was the phenotype of female mice undergoing remodeling. While a
mammary-specific Jak1 deletion had no effect on mammary gland development prior to
or during pregnancy, involution was strongly delayed, evidenced in the sustained
maintenance of the mammary epithelium, failure of matrix remodeling, and absence of
activated STAT3. This phenocopies the STAT3 and LIF-deficient models, and highlights
that JAK1 is crucial for mediating the effects of IL-6 class cytokines.
Surprisingly, JAK1 not only contributed to the activation of STAT3, but also to the
phosphorylation of STAT1 and STAT6. While these two transcription factors are active in
the developing mammary gland and early stages of pregnancy, development of JAK1deficient mammary glands were indistinguishable from wildtype. This may be attributed
to knockout models of STAT1 and STAT6 demonstrating their effects in the stroma [54,
55],
The previous studies of JAK2 along with the results in Chapter 3 indicate that the
Janus kinases may have non-redundant roles in STAT activation. Evidence is seen in
data of JAK2 deletion leading to inactivation of STAT5 in the mammary gland, with no
compensation by another kinase [60, 112]. JAK1-deficient mammary epithelial cells had
no effect on STAT5 activation downstream of PRL signaling but failed to phosphorylate
STAT3. This signifies that the two kinases may not have functional overlap during
mammary gland development. Understanding the role of the Janus kinases exemplifies
the importance of targeting kinases according to function and STAT activation.
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Across several types of cancer, such as head and neck squamous cell
carcinoma, melanoma, and breast cancer; STAT3 is demonstrated to be a contributor to
malignant disease [70, 104, 113]. The function of STAT3 appears to support migration
[35]. In breast cancer, 20-30% of cases exhibit amplification of HER2/Neu, which
contributes to a growth regulatory network that sees a high prevalence of active STAT3
driving aggressive disease and contributing to metastasis [114-116].
Comparing normal mammary gland development to breast cancer, STAT3
appears to have opposing functions. During postlactational remodeling, STAT3 is
essential for cellular breakdown and apoptosis, compared to its described role in breast
cancer where it drives growth and aggressive disease. Although in development STAT3
was described as necessary for initiating apoptosis during the remodeling process, this
is one facet of the involution phase. Several other important components are occurring
as well, such as upregulation of matrix metalloproteinases to degrade the underlying
matrix and allow the cells to detach from the basement membrane. In this way, STAT3
may be preferentially active in established disease to promote aggressive phenotypes.
We proposed to address the contribution of JAK1 to activating STAT3 in the
context of tumor formation and disease progression by generating in vivo cohorts that
express the neu oncogene in a mammary-specific manner, while the experimental group
also had Jak1fl/fl locus deleted prior to disease formation using the mammary-directed
Cre recombinase. If JAK1 maintains nonredundant activation for STAT3, as shown in
normal development profile, it may display biological relevance in mediating the
migration properties associated with STAT3.

Results
JAK1-deficient MMTV-neu tumor model displays absence of metastatic disease
while tumor onset remains unaffected
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Janus kinase 1 is necessary for the activation of STAT3 in immortalized
embryonic fibroblasts and is the key mediator of inflammatory cytokine signaling in the
mammary gland during the postlactional remodeling events during development,
coupling the IL-6-class ligands to downstream effectors through STAT3 [86]. The high
prevalence of tyrosine phosphorylated STAT3 in aggressive cancers, and STAT3’s
association with driving proliferative disease, led us to test if a JAK1-deficiency in the
mammary gland-specific ErbB2-driven tumor model would experience differential tumor
onset or malignant progression. In order to study the tumorgenesis profile, we generated
a mouse model that overexpressed the ErbB2 gene specifically in the mammary gland
concurrent with a mammary-specific deletion of Jak1 in the same epithelium, and also
tracked with a GFP reporter (MMTV-neu MMT-Cre Jak1

fl/fl

CAG-LSL-GFP). As the

MMTV promoter is expressed within the luminal and myoepithelial compartments during
development, both oncogene expression and the deletion of the floxed alleles occur
within the same cell. Latency of MMTV-neu-driven mammary tumors is approximately
220 days, and MMTV expression occurs well before puberty, thus producing Jak1deficient cells prior to tumor onset. The littermate controls lacked Cre recombinase,
preserving the Jak1fl/fl , rendering it wild-type (MMTV-neu Jak1

fl/fl

CAG-LSL-GFP). Both

experimental and control female mice were bred twice to induce proliferation and
expansion of cells in the mammary gland, and monitored for mammary lesions by
palpation biweekly for up to 12 months. Histological observation of control and knockout
glands depicted normal patterning of ductal branching and alveologenesis. Also the
absence of negative selection in Jak1-deficient cells was noted by observing the Cremediated expression of the GFP reporter in the mammary glands (Fig. 4.1A). Analysis of
39 tumor-bearing control females and 14 JAK1-deficient mice revealed that the tumor
onset did not vary statistically between the two groups (Fig. 4.1B). At the time of
necropsy, the resected tumors were analyzed for GFP, if induced by Cre recombinase,
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and analyzed as well for evidence of metastatic lesions in the lung, as the MMTV-neu
model is well-documented to readily metastasize to the lung [114]. Consistent with these
reports, the control females demonstrated lesions to the lung, identified by GFP,
interestingly, the JAK1-deficient females had no comparable lesions in pulmonary tissue
(Fig. 4.1C). This observation raises a critical question on the need for JAK1 during tumor
initiation versus disease progression.

Janus kinase 1 is necessary for the activation of STAT1, STAT3, and STAT6 in
mammary tumor epithelium in vivo and tumor cells in vitro.
To assess if JAK1 maintained regulation and activation of STAT3 in tumors,
Western blot was performed on control MMTV-neu mammary tumor lysate alongside
tumors from mice deficient JAK1. The results demonstrate that even in the disease
setting, an absence of JAK1 correlated with a deceased activation of STAT3, along with
tyrosine-activation of STAT1 (Fig. 4.2A). The activation of STAT6 was not evident in the
control tumors, when compared with cells stimulated with IL-4 (Fig. 4.2A).
Immunohistochemistry was performed and staining displayed strong nuclear staining of
activated STAT3 within control tumors; interestingly, the strongest signal was produced
along the leading edge of the tumors and near blood vessels. In comparison tumors
deficient in JAK1 had a marked decrease of active STAT3 within the tumor tissue, yet
retained activity in the stroma (Fig.4.2B). When immunostaining was performed for
localizing phosphorylated STAT1, low levels were seen within the tumor, consistent with
the decrease in protein expression by Western blot (Fig.4.2B).
In order to verify the tumor intrinsic characteristics with a lack of JAK1, isogenic
cell lines were derived from control mice harboring the Jak1fl/fl alleles, deleting Jak1 by
viral mediated Cre recombinase. The confirmed excision of JAK1 by immunoblot was
followed by an inhibition of STAT3 activity (Fig. 4.2C). The deletion of JAK1 also led to a
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significant decrease in active STAT1. STAT6 demonstrated the same lack of
phosphorylation in the knockout cell lines when stimulated with IL-4, as the cells did not
express active STAT6 at steady state levels (Fig. 4.2C). The Jak1-deficient cells had no
growth deficiencies while in culture, consistent with reports from STAT3-deficient
epithelial cells [35]. Although curiously, their phenotype changed from a stretched
cobblestone, spindle appearance, to a compact epithelial morphology in the absence of
JAK1 (Fig.4.2D).

A lack of JAK1 drastically decreases tumor growth of transformed cells in vivo
and reduces incidence of metastatic disease.
While tumor initiation and tumor progression are commonly associated as the
same events, they are two very different biological processes, requiring distinct
mechanisms for initial transformation of cells to sustained proliferation and migration
capacity. To address the function of JAK1 in mediating progression of disease, the
isogenic cell lines were treated by lentiviral infection, incorporating a luciferase reporter
construct for in vivo bioluminescence to monitor for growth and distant disease. Cells
were transplanted into the number 4 mammary glands of recipient female mice. 15 mice
per group were transplanted with 1x106 tumor cells per gland (total of 30 transplants per
cell line were performed) and monitored weekly for growth using calipers and
bioluminescence. Over the course of 8 weeks, the wild-type cells engrafted and
proliferated robustly, indicating that they maintained their neoplastic properties, strikingly
the isogenic-matched JAK1-deficient cells appeared to have engrafted, as indicated by
the continued bioluminescence assays, but demonstrated a lack of proliferation as
compared to the wild-type cells within the same amount of time (Fig. 4.3A, B). At
necropsy, the mice transplanted with the MMTV-neu tumor cells carried metastasis
within the lung, along with two mice presenting with metastasis in the liver and pancreas.
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Assessment of the lungs and pancreas of the mice transplanted with the JAK1-deficient
cells found no evidence of metastatic disease (Fig.4.3C). Verifying that transplant had no
effect on the activation of STAT3, the tumors were subjected to immunblot, confirming
the sustained STAT3 phosphorylation in wild-type cells and a maintained decrease in
JAK1-deficient transplanted cells (Fig.4.3D). Histological analysis of the transplanted
tumors of both wild type and knockout tumors demonstrated an invasive phenotype seen
in the wild-type tumors, as they lacked defined borders, while the JAK1-deficient tumors
maintained a compact phenotype. When the lungs were surveyed for metastatic
disease, distant disease was evident, and at time multifocal, while lungs of the mice
transplanted with JAK1-null cells remained free of disease (Fig. 4.3E). To ensure that
this was not an artifact of cell culture, minced tumor fragments from control and JAK1deficient tumors were transplanted into the number 4 glands of recipient female mice
(mice each cohort, total of 16 transplants performed) and monitored for growth. The
growth patterns mirrored that of the cell line transplants, although the knockout tissue
exhibited growth several weeks earlier, possible due to a selection of wild type or
unrecombined Jak1 floxed allelles. When the tumors were analyzed for active STAT3,
the control tumors as well as the resulting lung metastasis (Fig. 4.3G) were positive for
phosphorylated STAT3, indicating that active STAT3 may be important not only in the
primary tumor but also disease progression, and critical for the metastatic process and
propagation at the secondary site. The JAK1-deficient tumors continued to display very
little activation of STAT3 within the tumor, although the stroma contained persistent
STAT3 phosphorylation (Fig. 4.3G). While the signaling events necessary for tumor
formation seem independent of JAK1, these results evidence JAK1 as an integral
mediator of disease progression.

Signaling through JAK1 is required for cancer cell migration
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Prompted by the behavior of the transplanted cells, we performed in vitro assays
to verify migration characteristics. The trans-well migration assay demonstrated that the
migration patterns of the tumor cells were inhibited by a JAK1 deletion, reducing the
number of cells that migrated by nearly fifty percent and paralleling the same behavior
seen in vivo (Fig.4.4A). The results are consistent with the previous reports in STAT3deficient cells, that while the cell growth in vitro remained unchanged, migration was
impaired, suggesting that STAT3 acts in mechanisms associated with motility [35]. The
extent to which the JAK1-deficient cells lacked growth compared to the wild-type tumor
cells is reminiscent of data and phenotypes that depict the loss of tumor-initiating cells
[117, 118]. Performing a tumorsphere assay, we identified whether cells have the
required biological properties to generate tumors under low-attachment conditions.
Permitting the cells to grow for a duration of seven days, the wild-type cells readily
formed multiple spheres, meanwhile the tumor cells lacking JAK1 failed to proliferate
under the same conditions, synergizing with their behavior in vivo (Fig.4.4B). A marker of
tumor-initiating capability, specifically within the ErbB2-driven tumor population was
found to be CD61 [119], when we analyzed our control cells against the JAK1-deficient
cells, we observed a shift in the expression of the surface marker (Fig. 4.4C). The data
suggest that more than STAT3 is deregulated with the deficiency of JAK1.

Identifying target genes downstream of JAK1 signaling mediating tumor
progression.
To identify potential JAK1-dependent mechanisms that contribute to tumor
progression, we prepared cell lines for whole genome RNA-Seq analysis followed by
Gene Set Enrichment Analysis. Initially, five control tumor cell lines were compared
against four JAK1-deficient cell lines, validating the loss of JAK1 in a larger sample size.
241 genes displayed a significant deregulation by 2.5-fold change or greater, 185 genes
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were downregulated in the absence of JAK1 and 56 had increased expression in JAK1deficient cells, represented by a heat map of the top deregulated genes (Fig. 4.5A).
Deriving genes directly targeted by the JAK1/STAT3 signaling axis, analysis was
performed comparing the two isogenic cell lines. The top genes expressing the greatest
fold change by deregulation in the knockout cell lines are illustrated in Fig. 4.5B, the
focus for the following experiments expound on the genes with lower expression in the
JAK1-deficient cells, capitalizing on the function of STAT3 as a transcription factor. The
reversal of expression (lower Fig. 4.5B) may be a secondary result of JAK1 deletion.
Genes set enrichment analysis was performed on the isogenic cell lines, to identify
genes and functional pathways that may apply to biological processes. The deletion of
JAK1 led to the deregulation of downstream target genes associated with JAK/STAT
signaling, focal adhesion, and toll like receptor signaling (Fig. 4.5C). Specifically,
potential targets, such as Fos, Map3k8, and MyD88 were found downregulated in a
JAK1-dependent manner. The tumor susceptibility gene, Tpl2 (Map3k8) activates
pathways such as the MAP kinase and NF-κB, and has demonstrated transforming
capabilities [120], along with MyD88, whose expression integrates into the toll-like
receptor pathway to promote metastasis and proliferation [121]. Reinstating expression
of these targets in a JAK1-deficient background would identify their contribution to
disease progression.
Next, we validated the expression of putative JAK1 targets. A sizeable
downregulation was seen in the JAK1-deficient cells in the expression of the oncogene
Fos, as well as a known STAT3 binding target, Socs3. The Jak1 locus depicted the loss
of exon 2, supporting the fidelity of the sequencing and the identification of downstream
targets (Fig. 4.6A). Testing the expression and localization of select target genes on
tumor sections demonstrated a loss of platelet-derived growth factor alpha (PDGFA), the
STAT3 target OSMR, a reduction in CD14, large reduction in expression of BCL3 and c-
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FOS (Fig.4.6B). Immunoblot analysis confirmed the downregulation of the select targets
in the Jak1-knockout cell lines (Fig. 4.6C).

Re-expression of downstream JAK1-signaling target FOS partially rescues
growth-deficient phenotype
Expression of Fos was dramatically deregulated in the JAK1-deficient cells, as
identified by the RNA-Seq results (Fig. 4.6A), and perpetuated in the analysis by
immunostaining tumors wild type and deficient in JAK1 (Fig. 4.7A). Protein expression
was also concurrent in the cell line analysis by Western blot (Fig. 4.6C). Curious, we
postulated if this protein could rescue the growth-deficiency seen in the Jak1-knockout
tumors. To test this hypothesis, we generated a lentiviral construct to reinstate
expression of FOS in JAK1-deficient tumor cells. The cells were established and 1x106
cells transplanted into the number 4 mammary glands of recipient Athymic nude mice
and monitored for growth weekly. Tumors began to proliferate noticeably at week 6,
where the tumor size was considerably larger that the JAK1-knockout cells (Fig.4.7). The
partial rescue in growth of the FOS-expressing JAK1-defcient cells did not completely
mirror the growth patterns of the Jak1+/+ cells suggesting that complimentary factors
must be associated with growth in a JAK1-dependent manner. Further rescue studies
will describe additional proteins that can be tested in the same design, identifying and
validating critical effectors of JAK1 signaling. These studies may identify potent JAK1dependent targets necessary for in vivo tumor growth along with identifying genes
necessary for tumor-initiating capability.
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Fig. 4.1.
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Fig. 4.1. Characterizing a deletion of Jak1 during mammary tumor initiation and
progression. The GFP-based reporter identifies Cre recombinase activity. The deletion
of Jak1 (knockout, right) did not affect growth of the duct or the alveolar branching as
viewed by Carmine alum staining (A). Tumor onset was showed no statistical difference
between the control and experimental groups (B). Mammary tumors displayed GFPfluorescence, with lung metastasis seen in the lung of control mice, bar, 0.5 cm (C).
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Fig. 4.2.
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Fig.4.2. JAK1-deficient tumors display a lack of active STAT3 and STAT1 (A). The
whole tumors lysates also have active STAT1, which is absent in the knockout tumors.
STAT6 is not active within the tumors, when compared to cells stimulated with IL-4.
Immunohistochemistry demonstrates the localization of active STAT3 to the nucleus of
tumor cells, with staining evident tumors (T) as well as the surrounding stroma (S),
compared to a notable decrease to near absence of STAT3 staining in the tumor, but still
seen in the stroma. Bar,100 μm (B). Tyrosine-phosphorylated STAT1 is evident within
the control tumors, while decreased within JAK1-knockout tissue. Isogenic cell lines
were generated and verified for the presence of JAK1 in wild type cells (WT) and
deletion for Jak1 in the knockout cell lines (KO). JAK1 is shown to contribute to the
activation of STAT6 in the presence of IL-4 stimulation, as well as STAT1 at stead-state
conditions (C). Morphologically, the Jak1 wild type cells appear stretched, while a
knockout of Jak1 seems to drive them to cobblestone, epithelial appearance (D).
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Fig.4.3.
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Fig.4.3. In vivo growth of transplanted JAK1-deficient cells results in a severe
decrease in growth and occurrence of metastasis. To address the implications of a
JAK1-deficiency in established tumor cells, the isogenic cell lines were infected with a
luciferase construct to allow for bioluminescence tracking (A). The transplanted JAK1deficient cells displayed a large inhibition in growth compared to the JAK1 wild type cells
(A). The growth curve demonstrates the rapid growth of the control cells versus the
JAK1-deficient cells (B). The wild type mice displayed multiple lung lesions, as well as
metastasis to the liver and pancreas, while metastatic disease was absent in the Jak1knockout recipient mice (C). The transplanted cell line tumors were analyzed for STAT3
activity, and the knockout retained the muted activation of tyrosine-phosphorylated
STAT3 (D). Histology of the control mammary tumors and lung tissue presenting
metastasis (M), compared to the JAK1-knockout cell transplant mice display the
engrafted and formed tumor and lung tissue, bar 100 μm (E). Verifying that the previous
results are not an artifact of cell culture, whole tumors, JAK1 wild type, and JAK1deficient were minced and transplanted into recipient Athymic nude female mice. The
growth curve resulted in the similar trajectory of the transplanted cell lines (F). Analysis
of the transplanted tumor fragments depict the morphology by H&E of the wild type
tumors and lung tissue displaying metastatic disease (M), as well a tumor tissue from the
Jak1-deficient tumors. Control and knockout tissue was stained for phosphorylated
STAT3 (red), and luminal cell marker, CK* (green), demonstrating high activity with the
control tumor as well as the lung metastasis, while this was absent in the transplanted
knockout tissue, although active STAT3 was retained in the stroma (S) bar 100 μm.
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Fig. 4.4.
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Fig.4.4. The deletion of Jak1 results in decreased migration, tumorsphere
formation, and reduction in tumor-initiating cell marker CD61. The migratory
capacity of the wild-type cells (Jak1+/+) and JAK1-deficient cells (Jak1-/-) was tested by
trans-well assay (bar= 1 mm), decreasing migration nearly 50%, P= <0.05 (A). The cells
were then analyzed for tumor-forming capability by tumorsphere-forming assay. Wild
type cells (Jak1-/-) readily formed tumorspheres, while in the knockout cells (Jak1+/+), this
morphology was greatly reduced (B). Cells were tested for the cell surface marker
expression of CD61, a marker implicated in tumor-initiating cells and was found to be
decreased in the knockout cells (C).
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Fig.4.5.
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Fig.4.5. Whole genome RNA-Sequencing revealed the JAK/STAT, toll-like receptor,
focal adhesion, and ECM receptor pathways to be deregulated in a JAK1dependent manner. Five JAK1 wild type cell lines (Jak1+/+), and four JAK1-deficient cell
lines (Jak1-/-) were compared for differentially expressed genes (A). To compare the
JAK1-specific effects in a homogeneous population, the isogenic cell lines were
compared and the resulting heat maps display the top fold change of genes regulated in
a JAK1-dependent manner (B). Gene set enrichment analysis (GSEA) was performed
on the isogenic cell line data, and significant deregulated pathways are listed (C).
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Fig.4.6.
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Fig.4.6. Expression of JAK1 target genes confirmed by immunostaining and
Western blot analysis. The expression of Jak1 demonstrates the loss of exon 2 in the
knockout cell line samples (KO), highlighted by the blue-shaded area. Example targets
deregulated by decreased JAK1 expression are Fos and Socs3 (A). Targets identified by
RNA-Seq results were analyzed by immunostaining in wild type tumors (Jak1+/+) and
JAK1-deficient mammary tumors (Jak1-/-) and included PDGFRA, OSMR, CD14, BCL3,
c-FOS, SOCS3, and SOC1, bar, 100 μm (B). Select targets verified by Western blot for
protein expression, and displayed differential expression between the JAK1 wild type
(WT) and knockout (KO) cell lines (C).
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Fig.4.7.
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Fig.4.7. The re-expression of FOS partially rescues the growth-deficient phenotype
observed in the JAK1-deficient tumor cells. The expression of FOS in JAK1 wild type
tumors compared to JAK1-deficient mammary tumors, bar, 100 μm (A). Re-expression
of FOS in a Jak1 knockout cell line (Jak1-/-) restores levels of FOS at the protein level
(B). Transplanted FOS-expressing JAK1-deficient cells partially restores growth, and can
be tracked over the course of the study by bioluminescence, NC, negative control for
luciferase activity (C). cFOS expression by immunostaining demonstrates positive
staining in tumors wild-type for JAK1 (Jak1 WT) and JAK1-deficient, but expressing cFOS (Jak1 cKO + cFOS), while JAK1-deficient (Jak1 cKO) tissues are negative. Bar,
100 μm (D).
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Discussion
JAK1 plays a critical role in ErbB2-induced mammary cancer progression
The deletion of Jak1 in mammary epithelial cells prior to tumor onset did not
affect the tumor initiation; however, the JAK1-deficient tumors displayed a decrease in
active STAT3 and STAT1, as well as a decreased propensity to metastasize. The results
suggest that JAK1 is not crucial for molecular events involved in the initial transformation
of tumor cells, even though previous work has identified STAT3 in driving transformation
events [70]. Turkson, et al. demonstrated that STAT3, downstream of Src signaling,
could produce transformation in NIH3T3 fibroblasts [122]. A similar study, also using
NIH3T3 cells, showed a role for STAT3 in transformation as well as cell growth
downstream of tyrosine kinase receptors (TRK) [123]. It should be pointed out, that
these studies identified a role for STAT3-induced transformation in vitro, and while
STAT3 may promote transformation in 2D culture, it is either not activated in a JAK1dependent manner or necessary in vivo for ErbB2/neu transformation. The Neu protooncogene has been shown to induce tumor formation through intrinsic kinase activity
along with somatic mutations within the transgene, increasing the transforming
capabilities [114, 124]. Muthuswamy, et al. identified the Neu transforming capability to
also include recruitment of c-Src proto-oncogene (Src homology 2) for signal
transduction events [125]. Due to the unchanged tumor onset in the Jak1-deficient mice,
it is possible that these transforming events act independently of JAK1. Conversely,
early events initiate Akt for cell survival and proliferation, which is modulated by JAK2,
before becoming independent of this Janus kinase for fully transformed and established
cancer [79], underscoring the importance of signaling events for the various phases of
tumor progression.
Addressing tumor progression, our results synergize with ErbB2-driven tumor
models deficient in STAT3 [126]. Ranger, et al. reported that while there was no
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difference comparing in vivo tumor initiation of ErbB2 tumors that are Stat3+/+ versus
Stat3-/-, there was a significant decrease in the metastasis to the lung and concurrent
reduction in angiogenic response. We observed a similar phenotype of an absence of
lung metastasis in the transplant of isogenic cell lines and tumor fragments deficient in
Jak1, both of which displayed a lack of tyrosine-phosphorylated STAT3 in JAK1-deficient
samples compared to wildtype. The transplant data show that when placed back in vivo,
there was no indication of reactivation of STAT3, suggesting that another Janus kinase
family member cannot contribute to STAT3 activation in established disease in the
absence of JAK1. First, this potentiates the findings from Chapter 3, describing the role
of JAK1 in normal mammary gland development, where the deletion of the Janus kinase
1 produced a decrease in activated STATs 1, 3, 6. Also, decreased activation of these
transcription factors demonstrates that JAK2 could not compensate for their lack of
activation. In the mammary tumorigensis model, the observation that JAK1 contributes to
the activation of a similar STAT profile, which also cannot be rescued by another JAK
family member, supports the critical role for JAK1 in activating specific targets, namely
STAT3. These results demonstrate that inhibition of this kinase directly may provide
effective therapy for reducing the activity of STAT3 in established tumor cells, while
concurrently inhibiting their growth properties in Erbb2-driven human malignancy.

JAK1 contributes to the tumor-initiating cell population
The striking observation of the impaired growth of JAK1-deficient tumor cells
upon transplantation indicated a depletion of a tumor-initiating population of cells. The in
vivo results were replicated in vitro by tumorsphere analysis, as the ErbB2-driven Jak1+/+
cells displayed neoplastic characteristics and formed spheres readily in nonadherent
conditions, whereas Jak1-/- cells had a reduction in sphere formation. The results
indicate that the ErbB2 model is enriched in tumor-initiating cells, the minor subset of
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cells that are capable of propagating the bulk of tumors. The ErbB2/Neu tumorgenesis
drives luminal disease that has been shown to express elevated levels of integrin-beta3
(CD61) as well as increased amounts of CD49 [118, 127]. While the study by Vaillant, et
al. described the variation of tumor-initiating cells by CD61 expression in three mammary
tumor models, MMTV-wnt-1, MMTV-neu, and p53+/-, they concluded that the MMT-neu
was a homogenous population with little variation in a tumor initiating capability [127].
They arrived at this conclusion because they were not able to subdivide additional
populations of cells from the MMTV-neu tumors, such as Sca-1, CD18, and CD14. Our
data correlate with their findings, that MMTV-neu tumor cells are comprised of a luminal
population with high levels of CD61, although the level of CD61 expression is
dramatically decreased in the JAK1-deficient tumor cells. Interestingly, the expression of
CD61 correlates with capacity of cells to form spheres, supporting the hypothesis that
ErbB2 tumors are highly enriched for tumor-initiating cells. This finding implies that JAK1
may be implicated in the tumor-initiating cell population of established disease. The
tumor initiating cells have been suggested to be responsible for metastatic disease
[128], and may explain the reduced propensity of JAK1-deficient cells to metastasize.

Downstream targets of JAK1 signaling contribute to tumor growth
We found that the deletion of Jak1 in the Erbb2 murine tumor model establishes
JAK1 as the critical activator for STAT3 in a tumor cell-intrinsic mechanism. To identify
downstream targets of JAK1-mediated signaling, we performed whole genome RNASequencing and GSEA, identifying genes and pathways deregulated in a JAK1dependent manner. Among the targets identified were proto-oncogenes, Fos, and
Map3k8. Interestingly, these genes were also found to be deregulated in a JAK1dependent manner during remodeling events of the mammary gland as identified by
RNA-Seq and verified by immunostaining (Chapter 3, FOS data shown, Map38 data not
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shown). These data support that JAK1 maintains contribution to similar downstream
targets from normal development to established disease, pointing to a possible
conserved mechanism for their activation. We hypothesized whether either of these
targets would able to reinstate a growth, migratory, or tumorsphere-forming behavior, on
their own in the absence of JAK1.
In the first line of rescue experiments, we targeted FOS for re-expression, as the
proto-oncogene is recognized in cancer progression. FOS family members dimerize with
Jun to form the Activating Protein-1 transcription factor complex (AP-1), which affects
target gene expression. In the breast, oncogenic functions of FOS are described to
contribute to proliferation, loss of polarity, and implicated in aggressive ErbB2-positive
breast cancer [129, 130]. Re-expression of FOS partially rescued the in vivo growth
properties of the JAK1-deficient cells, although not to the degree of wild-type JAK1
tumor cells. Past studies have demonstrated that a knockdown of FOS inhibits MCF7
breast cancer cell proliferation [131] and correlated with our paired observations of
significant Fos deregulation in the JAK1-deficient cells combined reduced growth in vivo.
However, the replaced expression could not recapitulate a full growth profile compared
to JAK1 wild-type tumor cells. These results indicate that re-expression of FOS in a
JAK1-deficient background is not sufficient to drive cancer cell growth. Further studies
will identify if FOS contributes to migration and the tumor-initiating cell population. Our
observations indicate that JAK1 contributes to the expression and activation of a network
of genes that are necessary for driving growth in transformed cells. Further studies that
replace expression of deregulated targets will depict if there are direct targets of JAK1
signaling that promote the tumor-initiating cells and growth of the bulk tumor.
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Summary
The primary focus of our work explores the molecular regulation of the JAK/STAT
pathway and its relevance in signal transduction, promoting proliferation and cell
maintenance. Extensive work has described the role of STAT proteins in development,
along with their presence and activation in malignancy, much less has been explored in
relation to their upstream activators, the Janus kinases. Although JAK2 had been highly
characterized in the developing organ, little was known of the function of JAK1, the other
predominantly expressed Janus kinase in the mammary epithelium. The mechanism of
JAK2 is described to mediate PRL and GH signaling, driving the differentiation of the
alveolar cells through STAT5 [12, 13]. JAK2 was also thought to contribute to the
involution events, mediating the inflammatory cytokines and activating STAT3 to initiate
and promote the remodeling of the differentiated gland. However, JAK2 appeared to be
dispensable for activating STAT3 due to the observation of persistent STAT3 activation
in Jak2-deficient tumor cells [80]. Due to these observations, we questioned whether
JAK1 would play a crucial role in the postlactational remodeling events, mediating
inflammatory cytokine signaling. Furthermore, does JAK1 contribute to inflammatory
cytokine signaling in mammary tumorigenesis and disease progression?
We first began studies by developing a conditional knockout of Jak1 to bypass
embryonic lethality. We confirmed from the previously generated Jak1 conventional
knockout by Rodig et al. 1998, that JAK1 contributes to the activation of STAT3, and
additionally, the activation of two other transcription factors expressed in the mammary
epithelial tissue, STAT1 and STAT6. Followed by a targeted deletion in the mammary
gland. We saw no evidence of negative selection against Jak1-deficeint cells during
development, although importantly, we saw a striking phenotype by a massive delay in
involution. Further studies confirmed this delay was due to impaired mediation of the
inflammatory cytokines OSM and LIF, and also the absence in phosphorylation of
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STAT3. Using RNA-Seq, we identified an array of genes selectively regulated in a JAK1dependant fashion, and by ChIP-Seq verified binding targets of STAT3 versus STAT5.
Two of these targets were BMF and Bcl2l11 (BIM), both proapoptotic proteins that are
responsible for the initial breakdown of the mammary epithelial cells during involution.
This was verified first in silico, confirmed at the protein expression level in involution
samples of wild-type and JAK1-deficient tissue, and demonstrated biologically with
Bim/Bmf double knockout tissue during involution. These experiments confirmed the
integral function of JAK1 and its necessity for mediating STAT3 activation in response to
inflammatory cytokine signaling in mammary gland remodeling.
Next, we extended our findings to disease initiation and malignant progression.
There is a plethora of previous publications describing the association of STAT3 and
aggressive disease [70, 104, 132], and although efforts have been made to target this
transcription factor directly, success has been limited due to the inherent nature of
STAT3 existing as a latent factor in the cytoplasm. We targeted the deletion of JAK1
prior to tumor onset in ErbB2-driven mammary cancer, though we did not observe a
significant effect on tumor initiation, there was a defined reduction in the occurrence of
metastatic disease. To compare the effects on tumor progression, we established cell
lines from tumor mice bearing the Jak1fl/fl alleles and deleted Jak1 via viral-mediated Cre
recombinase. The cells that were deficient in JAK1 displayed a drastic decrease in
STAT3 activation. Also, when transplanted into recipient wild-type mice, the tumor cells
lacking JAK1 had a significant reduction in growth rate and no evidence of metastasis;
whereas tumor cells harboring wild-type JAK1 grew prolifically and metastasized to the
lung and in some cases the liver and pancreas. The substantial differences in the growth
rates indicated an effect on the tumor initiating cell population. Using tumorsphere assay
in vitro, we observed a striking decrease in the amount and size of tumor-forming cells.
RNA-Seq analysis identified deregulated genes that mirrored what we observed
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phenotypically, that the tumor cells had deregulation of adhesion molecules and
oncogenes (such as c-FOS) in a JAK1-dependant manner. Initial rescue studies showed
a partial rescue of the delayed growth of tumor cells. Further experiments will
demonstrate the genes and subsequent proteins necessary for tumor growth
downstream of JAK1/STAT3 signaling. Interestingly, when human breast cancer cells
lines which overexpress HER2 are depleted of JAK1, the same transcription factors
seen in the murine tissue—STAT1, STAT3, and STAT6—demonstrated a lack of
activation. Functional studies will illustrate whether JAK1 depletion has the same effect
in human malignancy as observed in our murine studies. If this is the case, then efforts
made to develop a JAK1-specific inhibitor would be advantageous for targeting active
STAT3 and preventing metastatic dissemination of breast cancers. The aspect of JAK1
affecting established cancer is pertinent, as the majority of clinically addressing
malignancies is for the treatment of established cancers.
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Future Directions
The findings from the biological impact of deleting Jak1 in neoplastic tumors were
surprising and left many questions to be answered. Namely, what are the tumor-initiating
roles of JAK1 in the primary murine tumor cells, and does the absence of JAK1 in
human cancer cells impart similar behavior observed in the murine cells? The following
experiments address JAK1, but also the downstream targets of JAK1 signaling, as well
as the effect of impacting human health by targeting JAK1 specifically by inhibitors.

Verifying the biological significance of JAK1-dependant targets
In continuation of identifying JAK1-dependant target genes responsible for
growth and proliferation, the target Tpl2 (MAP3K8) will be re-expressed. MAP3K8 has
been demonstrated to be a potent transforming factor in lung cancers as well as in
hepatocellular carcinomas [120, 133]. Little is known of its role in mammary tumor
progression. Results of re-expression in murine mammary tumor cells will verify its
transformation capabilities and potential to influence growth. Preliminary results indicate
that MAP3K8 is indeed an oncogene capable of reinstating neoplastic characteristics to
JAK1-deficient cells (Fig. 6.1).
To further verify the expression and JAK/STAT molecular pathways influencing
expression of these target genes, STAT3 activity will be re-instated in JAK1-deficent
cells by constitutive mutation of STAT3. The expression of STAT3 and the correlation
with increased expression of FOS and MAK3K8 would solidify the dependence of
STAT3 for transcriptional activation, which is regulated in a JAK1-dependant manner.
Verification by Western blot, qPCR, and immunostaining is expected to confirm
expression of the targets.
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Addressing the role of JAK1 specifically in ErbB2-driven cancer cells and breast
cancer tissue
In the previous chapter, we described the role of JAK1 contributing to the
activation of STAT3 along with STAT1 and STAT6 in murine Erbb2-driven tumor cells.
Extending the role of JAK1 into human disease, we generated a doxycycline-inducible
shRNA knockdown of human JAK1, and tested the knockdown on MDA-453 breast
cancer

cells,

which

overexpress

the

ErbB2

onco-protein.

Preliminary results

demonstrate similar findings, that JAK1 is necessary for the activation of STAT1, STAT3
and STAT6, in steady-state cell culture conditions (Fig. 6.2A). This contradicts previous
reports that promote the activation of JAK2 phosphorylating these downstream
transcription factors [134]. After verifying the knockdown of JAK1 in the human breast
cancer cell lines, RNA-Seq was performed and verified the knockdown of JAK1 in a Doxinducible manner (Fig. 6.2B). In conclusion these initial results are encouraging, as
perhaps the JAK1-knockdown in human cells may show similar behavior of the murine
counterparts. Additional future studies will need to address the growth pattern upon
transplantation and Dox administration, as well as mammosphere assays and migration
experiments. Additionally, we performed a JAK1-knockdown in the triple-negative cell
line, MDA 231, and the activation of STAT3 was also decreased, suggesting that JAK1
may have a role in regulating STAT3 expression across multiple breast cancer subtypes.
These results are encouraging, as triple negative tumors lack targeted therapy. The
inhibition of JAK1 could influence the growth and metastatic potential observed in the
previously described ErbB2 studies (Fig. 6.2C) (Chapter 4). To address the role of JAK1
in human breast cancer tissue, we are able to collaborate with Dr. Hallgeir Rui at the
Medical College of Wisconsin for staining human tumor samples. First, ERBB2-driven
cancer tissue can be stained for the presence of active STAT3 in human breast cancer
tissue. Protein expression could be analyzed by quantitative imaging for expression of
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STAT3 in various stages of breast cancer progression, such as pre-malignant tissue,
pre-treatment biopsies, post-treatment tissue, and recurrent disease. Next, the activation
of STAT3 would then be compared with the expression of targets identified in the
previous chapter such as FOS and the previously undescribed oncogene in the
mammary gland, Tpl2 (MAP3K8). The validation in conjugation with STAT3 levels would
support the method of using the expression of these targets as biomarkers for JAK1
inhibition.

Novel avenues to test JAK1 inhibitors for efficacy both in vitro and in vivo
We have the tools to directly assess the effects of current and developing
drugs/compounds targeting either Jak1 or STAT3 activity in cells deficient in Jak1.
Genetic knockouts biologically simulated the use of an inhibitor, by directly ablating the
function of a target. Using a novel inhibitor INCB039110, developed by Incyte, targeting
JAK1 could reveal the specificity of the compound and delineate off-target effects. The
compound, which has not been validated in an array of normal and transformed cells,
has been demonstrated to be well tolerated in topical application studies [135]. The
study could be constructed in a way to test the compound on epithelial cells,
exemplifying non-tumor samples, tumor cells wild-type for JAK1, and tumor cells
genetically deficient in Jak1. First describing the effects on non-tumor epithelial cells
versus immortalized and oncogenically-transformed epithelial cultures, comparing the
phenotypes and molecular downstream targets of the JAK/STAT pathway such as the
STATs themselves. This data could then be expanded, comparing the effects of the
inhibitor on tumor cells lacking JAK1 alongside matching wild-type tumor cells,
assessing the results for synergy of a JAK inhibitor on wild-type cells versus genetically
ablated kinase. Concise verification of the effects of drugs in vitro could be analyzed by
whole genome RNA-Seq, verifying differential gene expression. Building from the initial
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cell culture analysis, the in vivo application could be demonstrated by transplanting
MMTV-neu-driven cancer cells wild-type for JAK1, which have shown to engraft,
proliferate, and produce distant metastasis, or the Jak1-null tumor cells, into the
mammary gland of Athymic nude mice. This would provide several lines of evidence
describing the efficacy of the inhibitor. First, it would provide insight to the targeted
inhibition of JAK1 reproducing the same effects displayed in the previous study
described in Chapter 4, where a deletion in Jak1 inhibited tumor growth and metastasis
in transformed cells. This could be done is several stages to address the role of JAK1
extensively in tumor progression. The transplanted wild-type cells could be allowed
engraftment and inhibitor could be administered several days post-engraftment, when
the tumor is 0.5 cm in size, or the tumor could also be allowed to engraft, grow to a
select size, then biopsied with drug administration shortly after, observing the effects of
treatment on residual disease concurrently with its effect on metastasis. This
assessment in drug performance would mimic the clinical administration in human
disease, where a HER2+ breast cancer may be treated upon diagnosis, during
advanced disease, or adjuvant/post-operative therapy for refractory disease of the
primary tumor as well as controlling for present or potential metastatic disease. Moving
the studies to human breast cancer, HER2+ breast cancer cell lines that have been
stably infected with an inducible JAK1-knockout by shRNA in a doxycycline-responsive
manner, can also be used in vitro and in vivo (transplanted into Rag2-/-;Il2rg-/- recipient
mice), using the same inhibitor treatment strategy. Comparison of the transplanted mice
with the JAK1-knockdown via Dox alongside the inhibitor treatment would begin with
tumor measurement by calipers, followed by collection of tumors for molecular analysis.
Initial studies using Western blot would test for the deregulation of STAT proteins in a
JAK1-dependent manner. Analysis of previously identified targets of JAK1/STAT3

125

signaling would verify that the same targets are deregulated by the inhibitor similar to a
JAK1 knockdown or deficiency.
These future studies will provide valuable insight on the direct contribution of
JAK1 to breast cancer progression. Understanding the role of JAK1 and its downstream
effectors in established cancer will demonstrate the significance of clinically targeting
JAK1.
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Fig. 6.1.
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Fig. 6.1. Expression of MAP3K8 in JAK1-deficient cells demonstrates rescue of
neoplastic capabilities. Expression of MAP3K8 in cell lacking JAK1 activity
demonstrates loss of polarity in 2D cell culture (A) (view 10x magnification). Reinstating
MAP3K8 rescues the phenotype of JAK1-deficient cells (Jak1 KO) by producing
tumorspheres in low-attachment conditions
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Fig. 6.2.
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Fig. 6.2. Expression of JAK1 in human breast cancer cell lines corresponds to the
activity of STAT3. Using the ErbB2-driven human breast cancer cell line, JAK1 was
knocked down by inducible shRNA using Doxycyline. Knockdown of JAK1 demonstrates
reduced activation of STAT1, STAT3, and STAT6, by Western blot, similar to Erbb2driven murine disease (A). Initial studies of RNA-Seq depict the reduced expression of
JAK1 in a Dox-induced manner (B). Preliminary Western blot results of a knockout of
JAK1 in the triple negative cell line correlates with a decrease in phospho-tyrosine
STAT3, indicating a broad application of JAK1 regulating STAT3 in breast cancer (C).
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